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CBAPTER 1 
INTRODUCTION 
Endotoxins are cell wall lipopolysacharides of gram negative 
bacteria. The gut contains large numbers of bacteria and is 
generally accepted to be a large reservoir of endotoxins. In the 
normal state absorbed endotoxins are rapidly removed from the portal 
blood by especially the reticulo-endothelial cells of the liver. In 
patients with liver disease there is a diminished function of the 
reticulo-endothelial system, resulting in a raised frequency of 
systemic endotoxemia. Systemic endotoxemia in liver disease, as 
measured by the Limulus lysate test, correlates with a higher 
frequency of clotting disorders, renal failure and a high mortality 
rate. 
Interaction of endotoxins with macrophages results in the liberation 
of 
may 
mediators 
possibly 
such 
be 
as lysozyme 
responsible for 
and eicosanoids, and these 
the effects of endotoxin. 
Eicosanoids is the collective name for prostaglandins and leukotrienes. 
Eicosanoids are very potent mediators, which are thought to play a 
role in the pathogenesis of several diseases. For example, 
thromboxane A2, a potent platelet aggregator and vasoconstrictor, 
has been implicated in vascular diseases. Administration of 
endotoxins to experimental animals results in raised levels of 
thromboxane the stable metabolite of thromboxane 
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prostaglandin E2 , prostaglandin F2 and alpha 6 keto prostaglandin 
F lalpha. The raised thromboxane B2 levels are associated with shock, 
renal failure and a high mortality rate. As some of the circulatory 
and laboratory changes seen in patients with liver disease are 
similar to the effects of thromboxane A2 , it is conceivable that 
complications attributable to endotoxemia in cirrhosis might be 
mediated by eicosanoids. 
The aim of this study was to investigate the possible role of 
eicosanoids in the complications of liver disease, and to answer the 
following specific questions: 
l. Are plasma thromboxane B
2 
levels raised in liver disease ? 
2. Do raised plasma thromboxane B2 level.s correlate with the 
severity of liver disease ? 
3. Is thromboxane involved in the hemodynamic changes in liver 
disease ? 
4. What is the site of production and elimination of thromboxane 
B2 in liver disease ? 
5. Are raised plasma endotoxin levels correlated with raised 
plasma thromboxane B2 in liver disease ? 
6. Is it possible that portal hypertension and ethanol enhance 
the permeability of the intestine to endotoxins ? 
7. Do human peritoneal macrophages derived from patients with 
liver disease produce eicosanoids ? 
8. Is the ability to produce eicosanoids species and tissue 
dependent ? 
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CHAPTER 2 
PROSTAGLANDINS AND LEUKOTRIENES 
2.1 INTRODUCTION 
Eicosanoids is the collective name for prodtaglandins (PGs) and 
leukotrienes (LTs). Eicosanoids have received much attention during the 
last decade and are now thought to play an important role in the 
pathogenesis of several diseases. For example eicosanoids are involved 
in asthma (1 ,2), rheumatoid arthritis and other inflammatory diseases 
(3,4), cardiovascular diseases (5), renal diseases (6) and cancer 
(7,8). Synthetic prostaglandins have been used therapeutically in 
obstetrics, pediatrics and vascular diseases (9,10,11). 
The field of PGs and LTs is relatively new and complex and as a great 
part of this dissertation will deal with the eicosanoids, it is 
necessary to provide an introd1,1ction on the pathophysiology of these 
compo1,1nds. This section is not meant to cover all aspects of the 
eicosanoids but to summarize some characteristic properties of these 
extremely fascinating compounds. 
2.2 HISTORY 
In 1930 Kurzrok and Lieb found that fresh human semen produced 
contractions of the human 1,1terus (12). Goldblatt and von Euler 
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discovered that lipophilic compounds were the active components 
responsible for these uterus contractions (13 ~14).. Von Euler named 
these lipophilic compounds prostaglandins~ because they were thought to 
be- produced by the prostate (15).. Later it became clear that the 
majority of PGs production in semen was produced by seminal vesicles .. 
It was only in 1957 that BergstrOm et al isolated the first PGs, 
prostaglandin E (PGE) and prostaglandin F 2alpha (16) • In 1964 two 
independent groups of investigators~ namely van Dorp et al from the 
Unilever Research Laboratory, Vlaardingen, and BergstrOm et al from 
Sweden, showed that PGs were derived from essential fatty acids 
(17,18). 
In 1973 the unstable endoperoxides PGG2 and PGH2 were isolated by 
Nugteren and Hazelhof (19) and Hamberg and Samuelsson (20) •. 
Thromboxane A2 , initially described in platelets, but later in many 
other tissues, was found in 1975 (21). In 1976 Vane and associates 
isolated prostacyclin (PGI 2) (22). Borgeat and Samuelsson first 
described in 1979 the generation of several dihyd-roxy fatty acids by 
isolated polymorphonuclear leucocytes, following incubation with 
arachidonic acid (23). These substances were called leukotrienes, 
referring to their first established origin (leucocytes) and the 
presence of a certain chemical structure in their molecules, i.e. three 
conjugated double bonds (triene) typical for all these compounds (24). 
It became clear that slow reacting substance A (SRS-A) is a mixture of 
several peptidoleukotrienes (LTC4 , LTD4 , LTE4 ) (25) . For their 
discoveries concerning prostaglandins and related biologically active 
substances~ BergstrOm, Samuelsson and Vane received the Nobel prize in 
1982. 
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2. 3 PRECURSORS OF PROSTAGLANDINS AND LEUKOTRIENES 
The eicosanoids are formed from essential fatty acids (EFAs) having 20 
carbon atoms and three to five methylene-interrupted, unsaturated 
bonds, all in the cis configuration (26,27). The essentiality of 
dietary fat was first demonstrated in 1929 by Burr and Burr, who 
observed poor growth and skin lesions in rats raised on a fat-free diet 
(28). These symptoms could be prevented by the addition of linoleic 
acid to the diet (29,30). 
There are two fundamental fatty acids, linoleic acid and alpha-
linolenic acid, from which all other EFAs are metabolically derived 
(27,30) (Fig.!). Linoleic acid and alpha-linolenic acid cannot be 
synthesized by higher animals and need to be present in food (26). 
Linoleic acid is the major dietary EFA in humans (26,27,30). The 
structure of any EFA is fully described by three numbers, for example 
linoleic acid is Cl8:2W6; 18 is the number of carbon atoms in the 
chain, 2 is the number of double bonds andW 6 means the number of 
carbon atoms between the terminal unsaturated bond and the methyl end 
of the fatty acid. 
Linoleic acid, which is present in organ meats such as liver, milk 
products and vegetable seed oils, such as sunflower oil and safflower 
oil, is desaturated and elongated to the important arachidonic acid 
(C20:4 W6), via gamma-linolenic acid (Cl8:3w6) and dihomo 
gamma-linolenic acid (C20:3~) (26). 
Gamma-linolenic acid is especially found in evening primrose oil. 
Arachidonic acid (AA) is present in human milk, and in meat, some 
seaweeds and shrimps (26). The average daily intake of arachidonic acid 
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is 100-190 mg/ day which is more than enough for PGs production, which 
requires l mg/day (26). The other fundamental fatty acid, 
alpha-linolenic acid is present in sea food and is converted to 
eicosapentanoic acid (C20:~) (26,27,30). 
n-3 series n-6 series 
a linolenic c 18:3, w3 ·C18:2, w6 linoleic 
1 !::.. 6 desaturase 
octadeca C18:4, w3 C18:3, w6 y linolenic 
tetraenoic 
1 1 elongase 
eicosatetra czo: 4, w3 czo: 3, w6 dihomo y 
enoic 
1 1 
linolenic 
!:J. 5 desaturase 
eicosapen CZO:S, w 3 C20:4,w6 arachidonic 
taenoic 
Fig.l. The conversion of alpha linolenic acid and linoleic acid to the 
precursors of the eicosanoids. 
The enzymes involved in the desaturation and elongation of EFA are 
influenced by several factors, such as hormones, nutrition and ethanol 
(31,32,33). For example saturated fatty acids in the diet increase EFA 
requirement due to competition for the enzymes necessary for elongation 
and desaturation (27) . 
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During the last years much work has been done with EFA deficient diets 
(4,26,30,34,35,36). EFA deficient diets give rise to complex changes in 
animals and humans including changes in skin morphology and 
permeabili~y, pulmonary function, liver morphology, immunity and 
resistance to infections (30). In humans EFA deficiency occurred in 
patients receiving long term parenteral nutrition, before intravenous 
fat infusions were recommended (30). Infants treated with fat free 
parenteral nutrition for several months showed decreased growth rate, a 
typical skin rash and diminished resistance to infection (30). Some of 
these symptoms could be treated by giving linoleic acid or 
prostaglandins (30). Not only linoleic acid but possibly also 
alpha-linolenic acid is important in the diet to maintain health (30). 
The normal requirement of EFA in the diet is thought to be about 4% of 
the dietary energy (27). 
Dihomo-gamma-linolenic acid, arachidonic acid and eicosapentaenoic 
acid are the precursors of the PGs and the LTs (3,29) (Fig.2). 
Dihomo-gamma-linolenic acid, with three double bonds, gives rise to the 
1 series of prostaglandins as denoted by the suffix 1 (e.g. PGE1) and 
LTs of the 3 series; arachidonic acid, with four double bonds, is the 
parent compound of the PGs of the 2 series (e.g. PGE2)and 4 series of 
LTs (e.g. LTA4); and from eicosapentaenoic acid with five double bonds 
the prostaglandins of the 3 series (e.g. PGE3) and LTs of the 5 series 
(e.g. LTA5) are formed (3,24,29) (Fig.Z). 
The EFAs are found in esterified form in several lipid pools. The bulk 
of EFAs in mammalian cells are esterified in the fatty acyl chains of 
phospholipids in membranes (26,27). To a lesser degree the EFAs are 
present in cholesterol esters and triglycerides (26,27). Phospholipids 
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COOH 
dihomo y linolenic acid 
COOH 
arachidonic acid 
COOH 
eicosapentaenoic acid 
/ Prostaglandin 1-series 
~ Leukotriene 3-series 
- / Prostaglandin 2-series 
~ Leukotriene '!-series 
Prostaglandin 3-series 
Leukotriene 5-series 
Fig.2. Conversion of the three essential fatty acids to respectively 
the prostaglandins and leukotrienes. 
have a glyceryl backbone to which various groups are attached by ester 
linkages. Saturated fatty acids are linked mostly to position alpha and 
unsaturated fatty acids to position beta. The alpha1 position is 
esterified to phosphoric acid and to either choline, ethanolamine, 
serine or inositol giving phosphatidylcholine, 
phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol 
(37 ,38). Because EFAs have a predilection for the b'&ta position of 
phospholipids, arachidonic acid, the most abundant EFA in mammalian 
cells, is usually esterified to position B (26,27). The phospholipids 
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phosphatidylethonalamine phosphatidylserine and phosphatidyl inositol 
are thought to be rich in AA in position B. Phosphatidyl choline 
contains only a small amount of AA (4). Despite intensive investigation 
it is still not clear which phospholipid fraction contribute to most of 
the AA liberated. 
2.4 PHOSPHOLIPASES 
As eicosanoids are not stored in cells, biosynthesis must immediately 
precede release. Conversion of AA into eicosanoids does not take place 
unless AA is first released from phospholipids. As soon as the 
eicosanoids are formed they cannot reincorporate into the phospholipids 
(3,26). Phospholipids are attacked by several phospholipases (Fig.3). 
Fig.3. Sites of action of the phospholipases (PL). 
Phospholipase A1 liberates the fatty acid in position alpha and 
phospholipase A2 (PLAz) the mainly unsaturated fatty acid in position 
(37,38). Phospholipase C hydrolyses the glyceryl-phosphate bond to 
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liberate a phosphorylated base and a diglyceride. Phospholipase D 
cleaves the base from the phosphatide to yield phosphatidic acid 
(37,38,39) (Fig.3). 
Because AA is mainly localised at position , PLA2 is the main phospho-
lipase for eicosanoid synthesis (3,37). In platelets however, phospho-
lipase C (PLC) and a diglyceride lipase are possibly also responsible 
for AA release (40). Intracellular calci.um is thought to be a major 
activator of PLA2 and is therefore probably a major controlling factor 
in arachidonate liberation. However not everyone is convinced of the 
central role of calcium (41). 
Various stimuli other than calcium can activate phospholipases, e.g. 
mechanical disruption of membranes, immunological stimuli, bradykinine, 
several hormones such as pr'?lactin, non-enzymatic proteins and 
endotoxins (37,41). 
Phospholipase interaction with phospholipids not only results in the 
release of EFAs but also in lysophosphatides (37). Lysophosphatides 
might be modified by acyltransferases to yield phospholipids or might 
be further degraded by lysophospholipases resulting in hydrophilic 
glycerophosphonyl esters of the polar lipid head groups which are 
readily lost from the hydrophobic membranes. Lysophosphatides have well 
documented cytotoxic properties, which are responsible for several 
pathological states such as in pancreatitis, where lysolecithin 
contributes to several complications (42,43). 
Besides the obviously important role of phospholipases in the release 
of the precursors of eicosanoids it must be born in mind that there may 
be other pathways which lead to the liberation of these precursors 
(37). 
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In this way the complex system regulating phospholipids can be 
disturbed at several stages. For more detailed information of this 
system the reader is referred to the excellent reviews of Horrobin~ van 
den Bosch ind Irvine (26~38,39,41). 
2.5 SYNTHESIS OF EICOSANOIDS 
2.5.1 INTRODUCTION 
The EFAs, AA (C20:4,W6), dihomo-gamma-linolenic acid (C20:3,W6) and 
eicosapentaenoic acid (20:5,GJ3), released from phospholipids by 
phospholipase A2 can be transformed by at least two enzyme systems. One 
pathway is the conversion of these EFAs by the enzyme system 
cyclooxygenase to prostaglandins (PGs) and thromboxanes (TXA), the 
cyclooxygenase products (COP) (44). The other pathway is mediated by 
the enzyme 5-lipoxygenase to yield leukotrienes (LTs) (23). The PGs 
are those of the 1, 2 and 3 series and of the LTs those of the 3, 4 and 
5 series (27,29). The biological importance of the 1 series of PGs is 
not clear at the moment (26). The COP of the 3 series have received 
great attention because of the possible relation between a high intake 
of alpha-linolenic acid and a lo"" incidence of cardiovascular disease 
(45). Eskimos have a high dietary intake of long-chain 3 
polyunsaturated fatty acids from seafood and these fatty acids are 
thought to play an important role in the lot.7 incidence of 
cardiovascular disease (45,46). The explanation of the protective 
effect of C20:5WG formed from linolenic acid might be the absence of 
a proaggretory TXA3, t.7hile PGI3 as antiaggretory agent is as active as 
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PGI2 (47 ,48). However Hornstra et al could not confirm the protective 
role of eicosapentaenoic acid in the prevention of thrombosis and 
atherogenesis in experimental animals, so the protective role of COP of 
the 3 series is not certain (49). Because AA is the most abundant EFA 
in mammals the conversion of this EFA to its eicosanoids will be 
mainly discussed in the following part of this chapter. 
2.5.2 CYCLOOXYGENASE PATHWAY 
I Phospholipids I 
PLA 2 
J Arachidonic acid J 
cyclooxygenase 
PGG 2 
~ endoperoxides 
PGH 2 
.., .., v 'I' 
Fig.4. The conversion of arachidonic acid by the cyclooxygenase 
pathway. 
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After the liberation of AA from the phospholipids, it can be converted 
by the membrane bound enzyme, cyclooxygenase, to the endoperoxides, 
prostaglandin G2 (PGG2) and prostaglandin H2 (PGH2) (3,44) (Fig.4). The 
endoperoxides PGG2 and PGH2 are unstable with a half life of 
approximately 5 minutes (3,29). PGH2 is converted within the cell both 
non-enzymatically and enzymatically to the prostaglandins E2 (PGE2), 
prostaglandins FZalpha (PGFZalpha)' prostaglandin n2 (PGD2), 
prostacyclin (PGI2), throm.boxane A2 (TXA2), malondialdehyde (MDA) and 
12 hydroxy 5, 8, 10 heptadecatrienoic acid (HHT) (3,4,29) (Fig.5). 
The properties of the different products will be described in 
relation to different organ systems. Some general properties will be 
briefly mentioned here. PGE2 is thought to play a role in hyperalgesia 
and fever, and gives rise to dilatation of the vascular smooth muscle 
and the bronchial tree (2 ,50 ,51) and is an inhibitor of several 
functions of the macrophages (52a,53a). PGFZalpha is a vasoconstrictor 
and can constrict the bronchial tree (2). PGE2 and PGFZalpha induce 
relaxation of the longitudinal smooth muscles in the gastrointestinal 
tract (GIT) whereas PGE2 relaxes and PGFZalpha constricts the circular 
muscles of the GIT (52). PGI2, PGE2 and PGFZalpha play an important 
role in gastrointestinal diseases (52). PGD2 is produced by a number of 
different cells; at the moment only some effects are yet known such as 
bronchoconstriction, potentiation of the effects of histamine in the 
inflammatory action and inhibition of platelet aggregation 
(2,53,54,55). TXA2 is synthesized from PGH2 by the enzyme t.hromboxane 
synthetase. TXA2 is a very potent platelet aggregator and also 
constricts vessels and airways (3,53,56). In vivo the half life of TXA2 
is 30 seconds and it is converted into the biological inactive 
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OH 
COOH 
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o::) 
0 
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~COOH 
o-! 
--~ 
OH 
Prostacyclin 
Fig.S. Structure of cyclooxygenase products of arachidonic acid. 
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metabolite TXB2 (56). TXA2 can be produced by platelets, leucocytes, 
macrophages, mast cells, and human fibroblasts (3,56). PGI2 has a 
biological action which is exactly opposite to that of TXA2 , causing 
vasodilatat:ion and inhibition of platelet aggregation (3 ,56 ,57). 
Prostacyclin has a half life of 2 to 3 minutes and degrades 
spontaneously to 6 oxoprostaglandin F1 1 h (6 oxo- PGF1 1 h ) , which · apa apa 
is biologically less active (3,56,57). PGI2 is the main product of all 
arteries and veins and can be produced by heart, lung, stomach, kidney 
and uterus (3,56). It is thought that an imbalance in TXA2/PGI2 ratio 
provides an explanation for some pathological conditions such as in 
arterial thrombosis, myocardial infarction, diabetes, thrombotic 
thrombocytopenic purpura (56). 
2.5.3 TRANSPORT AND METABOLISM 
COP do not diffuse freely across cell membranes, so a transport system 
is required to remove them from the circulation. Transport mechanisms 
for PGE2 and PGFZalpha have been described and are very fast (29,57). 
The metabolism of COP leads to a marked loss of biological activity of 
these substances. The inactivation of COP in vivo is rapid: for example 
a single passage through the pulmonary circulation inactivates more 
than 90% of the circulating PGE or PGFZalpha (58). Inactivation of COP 
has been described in lungs, liver, spleen, kidneys and blood vessels 
(29,44). The enzyme system, 15-hydroxy-prostaglandin dehydrogenase 
(PGDH) initiates the breakdown of the prostaglandins of the E and F 
series by removing the hydrogen at the hydroxyl group at the C15 
position. They are subsequently reduced at carbon 13 by prostaglandin 
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reductase (44,2,58,59). This leads to the biologically inactive 
prostaglandin metabolite 13,4-dihydro-15-keto PG during the metabolism 
of the E and F type. Metabolism continues in the liver, with b€:ta 
oxidation and oxidation of the methyl and carboA~l chain, resulting in 
5,11 diketo-7- hydroA~ tetra nor prosta-1,16 dioic acids (44,58,59). In 
contrast to other COP, PGI2 is not metabolished by the lung but is 
degraded rapidly in the liver (29,57). For more detailed information of 
COP metabolism the reader is referred to the recent reviews 
(29,44,58,59). 
2.5.4 LIPOXYGENASE PATHWAX 
AA can be trans£ armed by the lipoxygenase pathway to leukotrienes 
(23,24), 5-hydroA~ eicosa 6,8,11,14 tetraenoic acid (5 RETE), 11-,12-, 
and 15 RETE (60,61,62). The most important pathway appears however to 
be the 5 lipoA~genase pathway, resulting in a family of biologically 
active substances named leukotrienes (61,62). After activation of the 
enzyme 5 lipoxygenase, AA is converted into the unstable peroxide 5 
hydroperoA;eicosatetraenoic acid (5-HPETE). This product can 
spontaneously be hydrolysed to 5-hydroxy-6-trans 8,11,16, cis 
eicosatetraenoic acid (5 HETE) or converted by a dehydratase to the 
unstable epoxide 5,6 oxide 7,9-trans-11,14- cis eicosatetraenoic acid, 
leukotriene A4 (LTA4) (61 ,63). LTA4 in turn can be converted 
enzymatically by an epoxide hydroxylase into 5(S), 
12(R)-dihydroxy-6,14-cis 8,10 trans eicosatetraenoic acid, leukotriene 
B4 (LTB4) (64). LTA4 can be conjugated with glutathione by a 
glutathionyl-S-transferase to form 5(S)-hydroxy-6(R)-S-glutathionyl 
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8 HETE 
9 HETE 
11 HETE 
12 HETE 
15 HETE 
other 
lipoxygenases 
Phospholipids 
Phospholipase 
Arachidonic acid 
5-lipoxygenase 
5 HETE +------- 5-HPETE l dehydrase 
LTA 4 LTB 4 1 glutathione-5-transferase 
LTC 4 1 y-glutamyltranspeptidase 
LTD 4 1 aminopeptidase 
LTE4 1 gluthaminic acid 
LTF4 
Fig.6. The conversion of arachidonic acid by the lipoxygenase pathway. 
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7,9 trans 11,14 cis eicosatetraenoic acid, leukotriene c4 (LTC4). LTC4 
is further metabolized by pep tides to generate leukotrienes D 4 and E4 
and F4 (61,62,63,64,65) (Fig.6 and Fig.7). 
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Fig.7. Structure of leukotrienes formed from arachidonic acid. 
Just as in the cyclooxygenase pathway, AA is the most important 
substrate for leukotrienes. However dihomo-gamma linolenic acid 
(20:3,(..16) and eicosapentaenoic acid (20:5,W3) too, are substrates for 
respectively LTs of the 3 and 5 series. There is evidence that these 
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LTs have qualitatively the same biological properties as the LTs of the 
4 series. Slow reacting substance (SRS), an important mediator in 
asthma and other types of immediate hypersensitivity reactions, is a 
mixture of LTC4 , LTD4 and LTE4 • SRS-A is thought to be released 
together with other mediators (for example histamine and chemotactic 
factors) after interaction between immunoglobulin E(IgE) molecules 
bound to membrane receptors and antigens such as pollen (65). 
The cysteine containing LTs (LTC4 , LTD4 and LTE4) are hundreds to 
thousands of times more active than histamine in contracting the guinea 
pig ileum (62). Intravenous administration of LTC4 , LTD4 and LTE4 give 
bronchoconstriction which can be blocked by the cyclooxygenase blocker 
indomethacine, suggesting that the bronchoconstriction is mediated by 
TXA2 and PGs (62,65). However LTC4 and LTD4 given as aerosal in guinea 
pig and man results in bronchoconstriction lasting for 30 minutes, 
which cannot be blocked by cyclooxygenase blockers (62,65). These LTs 
are 600-900 times more active as bronchoconstrictors than histamine 
(62). In vivo LTC4 , LTD4 and LTE4 give a short lived contraction of the 
arterioles, followed by a dose dependent and reversible leakage of the 
macromolecules, especially in the post capillary venules. They also 
cause constriction of the coronary arteries and large arteries 
(62,66,67). It must be born in mind that these experiments have been 
done mainly in animals and not in humans and that the effects of LTs 
are species dependent (67). Thus the exact role of LTs and its 
cardiovascular effects in men is not yet clear. The most potent LTs is 
LTD4 followed by LTC4• LTE4 has the lowest biological activity. 
LTC4 and LTD4 can be produced by human polymorphonuclears, human lung 
and peritoneal macrophages, eosinophils~ mast cells and possibly 
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Kupffer cells (62,68). 
LTB4 is a very potent chemotactic factor resulting in adherence of 
granulocytes to blood vessels and migration of leukocytes to areas of 
inflammation (64). 
LTB4 can be produced by polymorphonuclears, monocytes, lym.focytes, 
macrophages and mast cells (64,68). In several diseases elevated levels 
of LTS have been described, such as in asthma, psor:tasis, rheumatoid 
arthritis, gout and inflammatory bowel disease (62,70). 
2.6 EICOSANOID$ AND OBSTETRICS AND GYNECOLOGY 
Prostaglandins are involved at multiple levels in fertility regulation. 
They play an important role in the follicular rupture process (71), in 
subpriroate species they control corpus luteum function (72), they are 
active stimulators of uterine muscle contractility (73,74) and regulate 
the onset of labor (9). 
Dysmenorrhea includes a variety of signs and symptoms such as abdominal 
cramping, mood changes, headache, edema and frequently excessive 
menstrual flow. The disorder is a major cause of work loss by the 
female population. PGs and mainly PGF2alpha' which is a potent 
constrictor of the uterus myometrium, are thought to play a major role 
in this disorder (75, 76). The non steroidal anti inflammatory drugs 
(NSAIDs) block the cyclooxygenase pathway and are accepted as drugs of 
choice for treating dysmenorrhea (77,78) and menorrhagia (79). Besides 
PGF2alpha' PGI2 is also involved in dysmenorrhea (80). 
PGFZalpha regulates ovarian periodicity in cows, sheep and guinea pigs, 
but not in the human (81). This effect of PGF2alpha is of economical 
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importance because estrus 
administration of 
groups-of animals 
PGF2alpha' 
(81) • 
can be 
allowing 
synchronized by exogenous 
simultaneous insemination of 
In pregnant women there is a decline in progesteron production and an 
increase in PGs and oxytocine concentration during the last 24 hours 
before delivery (9,74). The PGs and oxytocin induce cyclic uterine 
contractions. The importance of PGs for the delivery is supported by 
the use of NSAIDs to prolong gestation and lengthen parturation (82). 
However the therapeutic use of PGs for induction of labor at term has 
not been utilized to a great extent, because of the side effects such 
as uterine hyperstimulation, gastrointestinal complaints and the risk 
of intrauterine closure of the ductus Botalli (74). Administration of 
PGs can induce labor at any time during the pregnancy. An analogue of 
PGF2alpha 15 methyl PGF2alpha has been used succesfully to induce 
abortion in the first and second trimesters of pregnancy (9 ,83). The 
abortion after intraamniotic injections of hypertonic saline is also 
probably caused by an interaction of oxytoxine and PGF Zalpha on the 
uterus (84). In addition to COP, leukotrienes may induce uterus 
contractions (62). 
2. 7 EICOSANOIDS AND THE LUNG 
In the lung prostaglandins are readily formed and metabolized. As 
mentioned before, PGDH activity, which initiates the breakdown of PGE 
and PGF series, is high in the lung (2,3). The main COP in the lung are 
PGI2 and TXA2 • PGI2 dilates the pulmonary vascular bed and airways 
(2,85), whereas TXA2 constricts the pulmonary vascular bed and airways 
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(85). The pulmonary complications of endotoxins, such as the early 
pulmonary vasoconstriction, are thought to be mediated by TXA2 (36). 
PGD2 and PGF2alpha are also pulmonary vasoconstrictors and broncho 
constrictors in man (85). PGE2 has weak dilatory effects on bronchial 
muscles. However in human allergic airway diseases, the Lis are 
considered to play a more important role than the COP, ai=way 
constriction in asthmatics being me~iated by histamine and Slow 
Reacting Substance A (SRS-A) (87). 
The characterisation of SRS-A as LTC4 by HPLC by Murphy et al was a 
large step forward in the research on asthma (25). At present LTC4 , 
LTD 4 and LTE4 are thought to be collectively responsible for the 
biological activity of SRSA (88). After ad~inistration of LTC4 or LTD4 
as aerosols to humans, a slow-onset, long-lasting bronchoconstriction 
occurs, which is not reversed by pretreating the subjects with 
cyclooAJgenase blockers (89). In contrast to the hyperreactive response 
to histamine in asthmatic patients, there is a similar 
bronchoconstrictor response to LTD 4 aerosols in asthmatics and normal 
subjects (89). 
Lis are hundred times more active than histamine in contracting human 
respiratory smooth muscles (65) and, in general, peripheral airways are 
more sensitive than central airways. 
Recently Creticos et al described the in vivo release of Lis in 
allergic patients. They found that intranasally administrated pollen 
grains in ragweed sensitive patients released in a dose-dependent 
fashion LTC, LTD and LIE in the nasal fluid, which correlated with the 
clinical response in these patients. Non-allergic patients had neither 
symptoms nor Lis release (90). Lung fragments obtained from patients 
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with extrinsic asthma generate large amounts of LTC4 , LTD4 and LTE4 
when challenged with the relevant antigen in vitro (91). 
Besides bronchoconstriction, LTC4 and LTD 4 increase the release of 
mucus from' human airways in vitro, constrict the pulmonary vascular 
bed, and increase vascular permeability (62). 
The possible pathogenic role of LTs in lung diseases is further 
sustained by the presence of LTs in sputum from patients with chronic 
bronchitis, emphysema and cystic fibr.osis (65). Further proof of the 
important role of LTs in the pathophysiology in allergic diseases, such 
as asthma, will, however, only be forthcoming if the use of selective 
LTs inhibitors alleviates the symptoms in these pati~nts. 
2.8 EICOSANOIDS AND THE VASCULAR SYSTEM 
The eicosanoids have extensive effects on vascular tissue and platelets 
in vitro. They have been suggested to play a role in atherosclerosis 
(5), thrombosis (29,93), myocardial ischemia (46,92), transient 
ischemic attacks (TIAs) (5, 93) and the vascular problems of diabetes 
mellitus (94). In these diseases interactions between platelet and 
vessel walls are considered to be responsible for eicosanoids 
production. 
The main cyclooxygenase product of platelets is TXA2 , a potent 
vasoconstrictor and platelet aggregator. In addition platelets 
synthesize 12-L-hydroxy 5,8,10 heptadecatrenoic acid (HHT), 
malondialdehyde (MDA) and only small amounts of PGD2 , PGE2 and 
PGFZalpha (4,29,95). Of the lipoxygenase products the monohydroxy acids 
12 and 15-HETE are mainly formed by platelets, which induce chemotaxis 
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of polymorphonuclear leucocytes (95). 
TXA2 synthesis by platelets can be stimulated by adenosine diphosphate 
(ADP) , epinephrine, dilute collagen and low doses of thrombin, which 
acti.vate membrane phospholipase, resulting in TXA2 formation. TXA2 in 
turn causes release of granules, resulting in platelet aggregation 
(5, 95). Platelet aggregation is however not solely dependent on TXA2 
synthesis, for it can be induced by thrombin and collagen independently 
of arachidonate metabolites (5,95). 
TXA2 synthesis can be blocked by PGE2 , PGD2 , PGE1 and PGI2 . PGI2 is the 
most potent inhibitor of platelet aggregation, and acts by raising the 
levels of cAMP in the platelets which block TXA2 production. 
In contrast to platelets where TXA2 is the main COP, in the vessel wall 
the main COP is PGI2 which has opposite effects to TXA2 , namely 
vasodilation and inhibition of platelet aggregation (57 ,59). Besides 
PGI2 the vessel wall can produce PGE2 , PGFZalpha' PGD2 and the 
lipoxygenase product 12 RETE (92). The ability of the vessel wall to 
synthesize PGI2 is greatest at the intimal surface and progressively 
decreases toward the adventitia (97). PGI2 production by endothelial 
cells is stimulated by angiotensin II, bradykinin, histamine and 
thrombin (5,95). Under certain circumstances the endoperoxides (PGG2 
and PGH2) derived from platelets can be utilized by vascular 
endothelial cells for biosynthesis of a phenomenon called 
endoperoxide steal (98). 
In view of the biological activity of TXA2 and PGI2 vascular diseases 
could be due to a dysbalance between TXA2/PGI2 production. The 
knowledge of the vascular effects of the lipoxygenase products are at 
the moment fragmentary and the pathophysiological role of these 
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substances in vascular diseases is a subject of much research. Some 
general properties of LTs will be mentioned~ which are mostly derived 
from experiments with animals and not from human studies. 
Leukotrienes c4 , n4 and E4 induce coronary, renal and systemic 
arteriolar constriction and augmentation of the permeability to 
macromolecules in postcapillary venules (66,67,99). At the moment there 
is no consensus about the effects of LTs on the blood pressure 
(95,99,100,101). The blood pressure reaction to LTs may be a species-
and a vessel wall dependent (95~100,101). 
The adventitia, also most abundant in macrophages and mast cells, is 
the main layer of the vascular wall to produce LTs. LTB4 has no direct 
vascular effects but gives adhesion of polymorphonuclear leucocytes to 
the endothelial lining of blood vessels (66,102). 
In atherosclerosis cholesterol is a clear risk factor. Under special 
circumstances cholesterol enhances TXA2 production and inhibits PGI2 
production (5,46). 
Thus atherosclerosis in man might be partly due to a disturbance of 
TXA2/PGI2 production. 
ln myocardial ischemia and acute myocardial infarction, raised coronary 
sinus TXB2 levels (46), and in angina pectoris, a reduction in 
prostacyclin platelet receptors have been described in man (103). The 
difficulty of these studies is that they do not show whether the 
changes in eicosanoids concentrations are a primary or secondary 
phenomenon. However because of the possible adverse effects of a 
dysbalance of TXA2/PGI2, many clinical trials have been carried out 
with COP blockers in the prevention of myocardial infarction. If all 
trials are pooled it appears that acetylsalicylic acid is of modest 
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benefit, reducing deaths by 16% and recurrent infarction by 21% (104). 
The disappointing results of NSAIDs in the prevention of myocardial 
infarction might be partly due to the high salicylate doses used in 
these studies. It must be born in mind that the high doses of NSAIDs 
used in these studies not only block TXA2 , but also PGI2 production 
(104,105). Further studies using low dose aspirin are needed to prove 
or disprove beneficial effects of thes; drugs in vascular diseases 
(104,106). The improved patency of aorta-coronary bypass by low dose 
aspirin is promising evidence for prevention of vascular diseases by 
low dose aspirin (105). The intracoronary administration of PGI2 in 
patients with acute myocardial infarction has been used in attempts to 
recanalize the obstructed coronaries, however not without side effects 
(107). In patients with peripheral vascular diseases prostacyclin 
infusions appear to be beneficial (96). 
Clinical trials with NSAIDs in patients with transient ischemic attacks 
(TIAs) (5, 108) aorto coronary vein grafts (106) and lower extremity 
bypass grafts (109) have given some positive results, but at the moment 
more controlled trials are needed to prove the beneficial effects of 
these drugs (104,105,106,109). 
Another therapeutic tool for ischemic vascular diseases might be 
dietary manipulation. As mentioned before, Greenland Eskimos, whose 
diet consists largely of fish, have a low incidence of myocardial 
infarction and increased tendency to bleed. Fish contains especially 
eicosapentaenoic acid, the precursor of the 3 series of prostaglandins 
and thromboxane. TXA3 , in contrast to TXA2 which is derived from 
arachidonic acid, does not have platelet aggregating activity, while 
PGI3 has the same vasodilator and platelet anti-aggregating effects as 
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PGI2 • This results in a diminished vasoconstriction and platelet 
aggregation in these patients. Humans fed a Western diet supplemented 
vtith cod liver oil had markedly changed membrane phospholipids which 
were associated with less reactive platelets and loWer blood pressure 
(47). Another important feature in patients with coronary heart 
diseases is the lower arachidonic and eicosapentaenoic acid levels in 
phospholipids and the low levels of dihomo-gamma linolenic acid and 
linoleic acid in adipose tissue in these patients (110,.111). These 
studies and the finding that 3 polyunsaturated fatty acid enriched 
diets in animals are associated with a reduction in size and sequelae 
of cerebral and myocardial infarctions should be a stimulus to further 
investigation to the role of diets in the prevention of vascular 
diseases. 
In several other diseases eicosanoids are thought to be important. For 
example the complications in diabetes mellitus may be partly due to the 
raised TXA2 and decreased PGI2 production (94) and in thrombotic 
thrombocytopenic purpura, characterized by formation of microvascular 
thrombo-emboli,. a deficiency of PGI2 generation has been suggested 
(112,113). Raised plasma and urinary TXB2 levels have been described in 
patients with borderline and manifest essential hypertension (114). 
Renal function and dysfunction might be partly due to changes in 
prostaglandin homeostasis (6,115). 
2.9 EICOSANOIDS AND THE GASTROINTESTINAL TRACT 
In the gastrointestinal tract (GIT) eicosanoids are involved at several 
levels. They play a role in GIT motility (52,116), gastric acid 
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secretion. (52,117), cytoprotection (52), peptic ulcer disease (118), 
diarrhea (52,116) and inflammatory bowel disease (119). 
Prostaglandins of E and F series affect smooth muscles of the GE tract. 
In _general, longitudinal smooth muscles are contracted by PGE and 
PGFZalpha whereas PGE relax and 
muscles of the GIT (120). PGD2 
PGF2alpha 
and PGI2 
contract the circular smooth 
have minimal actions on both 
muscle layers of the GIT, whereas T~ contracts bot b. smooth muscle 
layers (64,121). 
In vitro LTB4 contracts the smooth muscles of guinea pig duodenum, 
ileum and rat stomach probably due to stimulation of the cyclooxygenase 
pathway (64). LTC4 , LTD4 and LTE4 induce a potent smooth muscle 
contraction of the guinea pig ileum and rat stomach strip; these 
reactions are independent of the cyclooxygenase pathway suggesting a 
direct effect of LTs on ileum and stomach (62). The PG production is 
most abundant in the stomach and small intestines and least in the 
colon (116,117). For example the average basal gastric luminal output 
of PGE2 is 20 ng. per 15 minutes in healthy subjects (117). The mucosa 
has the greatest ability to synthesize PGs of the GIT wall layer (117). 
The effect of PGs on the GIT motility is dependent on the organ. In the 
esophagus PGs only affect the lower esophageal sphincter (LES) and not 
the upper esophageal sphincter or the motility of the body of the 
esophagus (52,116). Administration of PGE1 or PGE2 orally or 
'intravenously causes relaxation of the LES, whereas PGF2alpha and 
probably TXA2 , give contraction of the LES (52, 122). Indomethacin, a 
cyclooxygenase blocker, increases the LES pressure in humans, 
suggesting a net inhibitory role by PGs on LES pressure (116,122). In 
contrast to the intestines, PGs do not have a marked effect on gastric 
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motility in man (52). PGI2 might be an exception in view of the 
inhibitory effect on gastric emptying seen in animals. In the small 
intestine PGE and PGF2alpha augment gut propulsion, whereas 
prolongs small intestinal transit time (123). The therapeutic use of 
PGE derivates in peptic ulcer disease and obstetrics revealed a 
disturbing side effect, namely diarrhea. The diarrhea after 
administration is due to ·an enhanced motility of especially the small 
intestine and accumulation of fluid in the small intestine, called 
enteropooling (52,124). The importance of eicosanoids for motility is 
further sustained by the observation that. NSAIDs diminish the basal 
motility of the rabbit small intestine (125). The successful 
administration of PGs to animals to reverse postoperative ileus may 
lead to the evaluation of these compounds in patients with post-
operative ileus (126). These findings suggest that PGs and probably LTs 
are involved in the physiological and pathological motility of the GIT. 
The stomach is the most interesting target organ of PGs in the GIT. PGs 
block gastric acid secretion, provide cytoprotection against several 
drugs and compounds, and promote healing or prevent the development of 
gastric and duodenal ulcers. In experimental animals and humans PGA, 
PGE2 , PGE1 and PGI2 inhibit gastric secretion by reducing volume, acid 
secretion and pepsin output in vitro and in vivo (52,117,127). 
PGFZalpha has no antisecretory effect (116). The stimulatory effect of 
histamine,/ pentagastrin and food on gastric acid secretion can be 
totally abolished by PGs (52). The naturally occurring PGs have only in 
high concentrations an effect on gastric acid secretion (127). This 
might be due to the rapid metabolism of PGs to inactive metabolites by 
stomach tissue, liver and lung. Several analogs of PGE have been 
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synthesized which can be administrated orally, and they have been found 
to be 50 to 100 times as potent as PGE2 in inhibiting gastric acid 
secretion (117). Most of these PGs have a methyl group attached to 
carbon 15 or 16, e.g. 15(R) - 15 methyl PGE2 (ArbaprostilR, Upj.ohn, 
Michigan) 15 (S); 15 methyl PGE2 and 16, 16 dimethyl PGE2 . These 
compounds cannot be inactivated by the 15 PGDH and the reductase enzym 
system, which is the reason for the better and longer lasting 
inhibition of gastric acid secretion than that given by naturally 
occuring PGs (128). In a dose of 1.7 ug./kg. of 16, 16 dimethyl PGE2 
there is almost total inhibition of acid secretion, whereas doses of 1 
mg. of PGE2 are needed to provide the same antisecretory effect as 16, 
16 dimethyl PGE2 in man (117 ,127). The exact mechanism whereby PGs 
block gastric acid secretion is still not clear. 
PGs protect the gastroduodenal mucosa in at least two different Yays. 
Firstly PGs protect the gastric mucosa by inhibiting gastric acid 
secretion and secondly t:hey have protective actions on gastric mucosa 
independent of gastric acid inhibition, a phenomenon called 
cytoprotection (52 ,129). Inhibition of gastric acid secretion is a 
general property of several anti-ulcer drugs such as the histamine 2 
receptor blockers, cimetidine and ranitidine, PGs, anticholinergic 
agents and antacids (52). However cytoprotection of the gastric mucosa 
by PGs against damage by several drugs and necrotizing agents is an 
unique property of PGs which has not been described for R2 blockers, 
antacids or anticholinergic agents (52,117,129). Cytoprotection can be 
divided in direct cytoprotection and adaptive cytoprotection. Direct 
cytoprotection can be produced by the administration of PGs, which 
protect against gastric injury by NSAIDs or necrotizing agents (52). 
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Adaptive cytoprotection is the mechanism whereby mild irritants elicit 
endogenous formation of PGs, which protect the gastrointestinal 
epithelium against several necrotizing agents (52). The NSAIDs block 
the endog_enous formation of PGs, resulting in gastric erosions, acute 
upper gastrointestinal hemorrhage and an increase in fecal blood loss 
in healthy subjects (130, 131, 132). These drugs are frequently used in 
patients with rheumatic diseases and the gastrointestinal side effects 
such as ulcerations of stomach and small intestine are the most common 
reasons to withdraw the drugs in these patients. The NSAID-induced 
lesions can be prevented by antisecretory agents such as 
anticholinergic agents, ant.ihistaminics, antacids and PGs (52). The 
prevention of such lesions by these compounds are a direct consequence 
of the antisecretory aC'tivity (129). However administration of PGs in 
concentrations which have no antisecretory effect and even PGs devoid 
of gastric ant.isecretory activity still prevent NSAIDs lesions, in 
contrast to low doses of antacids, antihistaminics or anticholinergic 
drugs (52,133,134,135). Severe gastric necrosis produced by strong 
irritants such as absolute ethanol, thermal injury, hypertonic 
solutions of HCl, NaOH and NaCl and taurocholate are totally prevented 
by pretreating the animals with PGs. Robert called this property a 
direct cytoprotective effect of PGs by an as yet unknown mechanism 
(52). One possible explanation for this cytoprotective effect might be 
the increased mucus production after PGs administration (136). 
The protective effect of mild irritants is mediated by endogenously PGs 
production of the gastric mucosa. This effect of mild irritants can be 
totally abolished by indomethacin (52,135,137). 
In peptic ulcer disease there is no absolute deficiency of PGs but 
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rather a diminished PGs synthesis after duodenal acid load (138). 
Because of the antisecretory and cytoprotective properties of PGs for 
gastric mucosa, several double-blind, multicentre trials have been done 
to ·investigate the effectiveness of PGs in healing peptic ulcers 
(117,118). Both gastric and duodenal ulcers healed significantly faster 
after treatment ;.rith PGE2 in comparison ;.rith placebo (116,117 ,118). 
Ro;.rever studies comparing PGs with antihistaminics ranitidine and 
cimetidine need to be done to define the place of PGs in peptic ulcer 
disease. Sucralfate, an aluminium salt of sucrose octasulfate, is an 
effective drug in treating and preventing peptic ulcer disease, and 
this effect is PGs dependent (139). 
In the small intestine PGs have, as mentioned before, effects on 
motility, cytoprotection and on secretion of water and electrolytes. 
(52). Enteropooling can be induced by PGFZalpha and PGE2 in animals and 
men (52,119,140). High doses of PGE2 cause a secretory diarrhea, 
whereas PGI2 and PGD2 have an anti-enteropooling activity (52). PGs 
have been implicated in diarrhea due to exotoxin-producing bacteria, 
inflammatory bowel disease, radiation enteritis, some endocrinologic 
diseases and some laxatives (52,116,119,141). In Crohn's disease and 
colitis ulcerosa raised levels of PGs, l2EETE, l5HETE and LTB4 have 
been found in luminal secretion, stools and mucosa (119,142,143,144). 
Some investigators have claimed that 5 amino salicylic acid (5 ASA), a 
product of sulfasalazine, exerted it's effects by blocking the 
cyclooxygenase pathway. Recent studies, however, show that 5 ASA not 
only blocks the cyclooxygenase but also the lipoxygenase pathway (145). 
This might be the explanation why NSAIDs which block only the 
cyclooxygenase pathway are not effective in inflammatory bowel disease 
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(146). The results of numerous studies suggest important roles of PGs 
and LTs in the GIT. More studies, ho~ever, need to be done to sho~ that 
the c~anges in PGs and LTs in disease are not merely epiphenomena. 
2.10 EICOSANOIDS AND THE LIVER 
The liver plays an important role in the metabolism of eicosanoids 
(58,147). The liver is the main organ for metabolism of PGI2 , ~hich 
cannot be inactivated by the lung (148). The hepatic metabolism of PGI2 
results in the formation of several biologically inactive lipids and 
one biologically active product named 6-keto-PGE1 , 6-keto-PGE1 is a 
vasodilator and potent inhibitor of platelet aggregation (148). In the 
liver PGD2 can be converted to PGF2 by prostaglandin 11-keto alpha 
reductase (149, 150). Thus the liver is able to convert a potent 
inhibitor of platelet aggregation to a potent vasoconstn.ctor without 
effect on platelet aggregation. Knowledge of LTs metab0lism is 
fragmentary. Recently Uehara et. al reported that intravenously 
administrated LTs are rapidly taken up by hepatocytes and excreted in 
the bile (147). These findings suggest that the liver has a role in the 
removal of biologically active eicosanoids from the circulation. 
Hepatic injury might impair this process and lead to prolonged and or 
augmented actions of eicosanoids in various organs. It might also be 
possible that eicosanoids taken up by the liver may contribute to the 
development of hepatic diseases (151). 
The liver not only metabolizes but also synthesizes several eicosanoids 
leukotrienes such as PGE2 , PGFZalpha' PGD2 , TXA2 , PGI2 and probably 
(152,153,154,68). Isolated liver cells can synthesize a scala of 
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eicosanoids. For example hepatocytes stimulated by vasopression produce 
TXB2 (155) and Kupffer cells can produce PGE2 ~ PGD2 , PGFZalpha~ PGI2 
and TXA2 and leukotrienes after stimulation with endotoxins~ calcium 
ionophore or zymosan (68, 156, 157). Phospholipase A2 can enhance TXB2 
and 6-keto-PGF 1aipha release from the isolated perfused rabbit liver 
(154). Liver disease might therefore influence not only metabolism but 
also synthesis of eicosanoids. Some of the deleterious effects of liver 
disease might be mediated by eicosanoids, whereas other eicosanoids 
could protect the liver against several toxins. PGI2 has been suggested 
to be involved in the development of portosystemic collateral 
circulation in rats with portal hypertension, to enhance hepatic blood 
flow in man and dogs and it is also a very potent stimulus for renin 
release (158,159,160). 
The 16~16 dimethyl PGE2 analogues have been succesfully used to protect 
the liver against several hepatotoxic drugs such as alpha 
napthylisothiocyanate (161), bromo benzene (162) ~ galactosamine (163) ~ 
carbon tetrachloride (164). Severe liver damage by ischemia can be 
prevented by PG administration (165). Besides the protective effects of 
these prostaglandins, another COP namely TXA2 is thought to be the 
cause of several complications in liver disease (115~166). In patients 
with alcoholic liver disease we found raised plasma TXB2 levels, which 
were associated with higher levels of serum urea, a more disturbed 
liver function as measured by an increase in alkaline phosphatase and 
gamma glutamyl transpeptidase and a decrease in antiplasmin and 
antithrombin III levels (166). In the hepatorenal syndrome raised 
urinary TXB2 and lowered PGE2 levels have been found (ll5). These two 
observations suggest a potential role for TXA2 for the complications in 
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these cirrhotics. The raised levels of TXB2 in liver disease might be 
secondary due to the high frequency of endotoxemia in these patients 
(166~167). In vitro and in vivo studies have shown that the deleterious 
effects of endotoxemia are mediated by several eicosanoids (168~169, 
170). Endotoxins, preferentially taken up by Kupffer cells, induce 
eicosanoids production which then give rise to several complications 
seen in patients ~ith liver disease (156,166). Non-selective or 
selective blocking of the cyclooxygenase pathway gave an undeniably 
better survival in experimental animals with endotoxemia and probably 
septic patients (168,170,171,172). Even endotoxin-induced liver damage 
can be prevented by NSAIDs (173). Based on these findings it seems 
reasonable to suggest a trial with NSAIDs in cirrhosis. However, 
inhibition of TXA2 production by the administration of NSAIDs, which 
not only block TXA2 but all COP, has been shown to cause renal failure 
in patients with liver disease (174,175,176). This is in agr~eme~t with 
the suggestion that some of the COP might be beneficial in liver 
disease (174,176,177). The use of selective TXA2 synthetase blockers 
such as dazoxiben in cirrhotics with portal hypertension and hepato-
renal syndrome was unfortunately not followed by changes in systemic, 
pulmonary and portal pressures nor was there an improvement of the 
renal function in the hepato renal syndrome (178,179). Further work 
needs to be done to unravel the exact role of TXA2 in the complications 
of liver cirrhosis. 
One possible explanation for the failure of TXB2 blockade in these 
patients might be that the raised TXB2 levels are a secondary 
phenomenon. Leukotrienes have been shown to stimulate the release of 
TXA2 in vitro and in vivo (180,181). It has been shown that especially 
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leukotrienes c4 and n4 give a potent. vasoconstriction of the isolated 
perfused rat kidney and decreased splanchnic blood flow (100,182). 
Administration of LTC4 to isolated hypoxic hepatocytes result in death 
of· approximately 95% of the hepatocytes, sugges'ting a direct toxic 
effect of LTC4 on hepatocytes (151). Halothane induced hepatic damage 
is possibly mediated by leukotrienes. 
The maintenance of renal function by eicosanoids and the use of NSAIDs 
in liver disease have been extensively studied (174,175,176,177). 
Patients with cirrhosis and ascites frequently develop a decrease of 
renal blood flow and glomerular filtration rate, secondary to an active 
renal vasoconstriction (183). This change can even result in functional 
renal failure called the hepatorenal syndrome, which is characterized by 
a marked reduction in renal blood flow without structural abnormalities 
of the kidney, suggesting a circulating agent as the cause (184). This 
proposition is further sustained by the fact that kidneys from a 
patient with the hepatorenal syndrome can be successfully transplanted 
in a patient with normal liver. Conversely, the kidney in a patient 
with the hepatorenal syndrome resumes function if the patient undergoes 
successful liver transplantation (184). It has been postulated that 
renal dysfunction in cirrhotics is caused by a dysbalance between 
vasoconstrictive agents such as TXA2 , angiotensin II, and the 
sympathetic nervous activity and vasodilating agents such as PGE2 (177). 
Several reports provide strong evidence that especially PGE2 , but also 
PGI2 play an important role in maintaining renal function in cirrhotics 
(175,176,177,185). These vasodilatory PGs are thought to pro'tect the 
renal function of cirrhotics from the powerful vasoconstrictors such as 
angiotensin II, symphatic nervous activity and TXA2 and probably 
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leukotrienes (177, 178,186). Raised urinary PGE2 have been found in 
cirrhotics with ascites without renal failure and there is a direct 
correlation between reduced urinary PGE2 levels and the severity of the 
renal failure in patients with cirrhosis (177). Boyer et al. first 
described the deleterious effects of NSAID administration in cirrhotic 
patients (174). Reduced effective renal plasma flow and creatinine 
clearance could be abolished by the administration of PGA1 ( 17 4) . 
Later, several other workers found that the use of NSAIDs in patients 
with severe liver disease resulted in decreased renal blood flow, 
decreased creatinine clearance, reduced urinary volume and sodium 
excretion. The NSAIDs enhance the pressor sensitivity to angiotensin II 
(177). These effects are paralled by the reduction of PGE2 (176). 
Several authors therefore conclude that NSAIDs should not be employed 
in patients with severe liver disease (175,177). Another interesting 
finding is that the renal response of furosemide in cirrhotics is 
mediated by PGE2 and that administration of furosemide protect these 
patients from developing renal insufficiency after administration of 
NSAIDs, probably due to enhanced renal PGs synthesis stimulated by 
furosemide (176). 
Ascites is a frequently encountered complication in cirrhotics. 
Stimulated peritoneal macrophages derived from ascites of experimental 
animals and patients with ascites due to liver cirrhosis can produce 
several leukotrienes such as LTB4 , LTC4 and LTD4 and in minor degree 
IXB2 and 6-keto-PGF1alpha (68,69,187,188,189). Thus several 
complications, such as renal dysfunction, shock, coagulation disorders in 
liver cirrhosis and especially those that occur after the insertion of 
a peritoneal jugular shunt might be (partly) mediated by eicosanoids 
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from the ascitic fluid which enters the systemic circulation (68,69,139, 
190). 
References: see page 163. 
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CHAPTER 3 
ENDOTOXINS 
3.1 GENERAL ASPECTS 
Endotoxins are cell wall lipopolysaccharides of gram negative bacteria 
with variable amounts of proteins and lipids (192,193). The 
lipopolysaccharide complex can be divided to three major parts: the 
0-polysaccharide, the R-core and lipid A (fig.l) (194). 
---------------------
--------------------
11 R11 -Core Lipid A 
non 
Fig.l. Simplified scheme of a cross-section of the cell wall of a gram-
negative bacterium. The wall consists of three layers: cyto-
plasmic membrane (CM)~ a peptidoglycane layer (PG) and the outer 
membrane (OM) with lipopolysaccharide which contains 3 parts: 
lipid A, R-core and the 0-polysaccharide. 
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The a-polysaccharide is chemically unique for each type of bacterium. 
The R-core is the middle part of the lipopolysaccharide molecule and 
links the 0-polysaccharide with lipid A (192). Lipid A is remarkably 
similar for a broad spectrum of gram-negative bacteria and is 
responsible for most of the biological effects of endotoxins (192,194). 
The gut is generally accepted to be a large reservoir of endotoxin 
producing gram negative bacteria. Small amounts of endotoxins are 
continuously taken up from the gut lumen and reach the liver with the 
portal blood. In the normal state, they are rapidly removed from the 
circulation by the Reticule Endothelial System (RES), especially by the 
Kupffer cells (195). After phagocytosis a variety of beneficial and 
toxic mediators are released from the macrophages (192,195,196). 
Endotoxins are involved in several diseases. For example a major factor 
complicating the treatment of gram-negative bacteraemia is the release 
from bacterial cell walls of endotoxins. For this reason these 
substances have been implicated in the pathogenesis of gram negative 
sepsis and shock (197). 
The clinical relevance of endot.<?xins in gram negative bacterial shock 
is sustained by two recent studies using antibodies to endotoxins in 
septic patients (198,199). Ziegler et al prepared human anti-serum by 
vaccinating healthy men with heat-killed Escherichia Coli J5, only 
containing a Core-Lipid A complex, which is very similar for most 
, bacteria strains. They found a better survival in the 103 patients, 
receiving antiserum, compared to the control group (198). In the other 
study freeze dried human plasma rich in anti lipopolysaccharide 
immunoglobulin was used in fourteen septic shock patients and reduced 
the mortality and morbidity rate in the treated group (199). These 
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studies indicate that treatment with anti lipopolysaccharide might be 
beneficial in patients~ where endotoxemia is suspected to be 
responsible for complications (198~199,200). 
A major problem interfering with prospective clinical studies is the 
difficulty in detecting endotoxins in biological samples. Endotoxins 
can be measured by the Limulus Amebocyte Lysate (LAL) test introduced 
by Levin et al (192~201). 
The principle of the LAL test for the detection of endotoxins is an 
endotoxin induced gelation of a clottable protein present in the blood 
amebocytes from Limulus polyphemus (201). For the detection of 
endotoxins in blood special precaUtions are needed, because of the 
presence of an inhibitor in human blood which interferes with the LAL 
coagulation (192). The limulus test with the aid of chromogenic 
substrate has been used in recent years and seems to be sensitive 
(detection limit 10 pg/m.l) ~ quantitative and reproducible (202,203). 
Radioimmunoassay (RIA) or ELISA (enzyme-linked-immunoabsorbent assay) 
have been developed but are not generally available. 
3.2 THE BIOLOGICAL EFFECTS OF ENDOTOXINS 
The biological effects of endotoxins are numerous and have recently 
been reviewed (192,193,195,204). Some of the effects are listed in 
table I. It must be born in mind that the biological effects of 
endotoxins are species and concentration dependent. Rats for example 
are rather insensitive whereas men and rabbits are highly sensitive to 
endotoxins (193,205). 
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Table I. BIOLOGICAL EFFECTS OF ENDOTOXINS 
Fever 
Complement activation 
Activation of clotting system 
Metabolic and hormonal changes 
Immunological reactions 
Thrombocytopenia and leucopenia 
Hypotension and shock 
Renal dysfunction 
Liver damage 
Release of eicosanoids 
Positive Limulus Amebocyte Lysate test 
Fever is a dose-dependent reaction after endotoxin administration and 
has been used as an in vivo test for the detection of pyrogens 
(193~197). The fever reaction is mediated by an endogenous pyrogen~ 
interleukin I, released from several cells such as leucocytes, 
monocytes, Kupffer cells and macrophages (195,197,206). Endogenous 
pyrogen exerts its thermoregulatory effects by acting on the 
thermoregulatory center of the anterior hypothalamus producing a change 
in the specific body thermostatic setting (197). 
In patients with sepsis due to gram negative bacteria diffuse 
intravascular coagulation is frequently seen. Endotoxins activate 
factor XII (Hageman factor) resulting in activation of the intrinsic 
pathway and activate the extrinsic pathway by the release of tissue 
factors of monocytes (193, 197,207, 208). Endothelial cells are damaged 
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and even torn off from their support resulting in a "Widespread source 
of activation of the clotting cascade. 
Thrombocytopenia after endotoxin administration is causPd by platelet 
aggregatiDn and the release of several active mediators such as 
platelet factor 3, ADP, serotonine, histamine and TXA2 (192~208). The 
massive microthrombosis induced by endotoxins appears to reflect a 
state of intravascular inflammation, leading to complement activation, 
leucocyte sequestration with release of lysosomal enzymes and other 
mediators and activation of the clotting and fibrinolytic system 
(207 ,209). Endotoxins give an initial leukopenia followed by 
leucocytosis. The leucopenia is due to sticking of the leucocytes to 
the vessel walls (193). Plasma withdrawn one hour after endotoxin 
injection significantly enhances the adhesiveness of leucocytes from 
control animals~ suggesting a circulating substance as the cause for 
the leucopenia (192). An important pathological effect after endotoxin 
administration is the hemodynamic changes sUch as systemic hypotension, 
diminished cardiac output, lowered systemic vascular resistance, renal 
insufficiency, splanchnic vasoconstriction and increase in pulmonary 
vascular permeability and pulmonary artery pressure (168,169,195,210, 
211). The hemodynamic changes are thought to be due to interaction of 
endotoxins with leucocytes, platelets, and the complement system 
resulting in the release of vasoactive substances such as eicosanoids, 
catecholamines, myocardial depressant factor, kinine, serotonin and 
his-camine (212,213). For example histamine is released rapidly after 
endotoxin injection and is thought to play a role in the early vascular 
and heroodyna~ic changes induced by endotoxins (195). 
Endotoxemia in septic patients and liver cirrhosis is correlated with 
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renal dysfunction (195 ~214). Renal function can be disturbed, 
independently of diffuse intravascular coagulation and systemic 
hypotension. Endotoxemia results in renal vasoconstriction, decreased 
urinary sodium secretion and even oliguria (171,195,211,214). 
3.3 ENDOTOXIN$ AND THE LIVER 
In the normal state endotoxins are rapidly removed from the portal 
blood by the Kupffer cells (204). By means of the Limulus Lysate Assay, 
endotoxins could be detected in portal blood in almost SO% of 120 
patients who underwent abdominal surgery. In only three patients 
endotoxins could be detected in portal and systemic circulation (193). 
The accumulation of endotoxins in the systemic circulation may take 
place in case of insufficiency of the Kupffer cell and or spill over of 
the portal blood into the inferior vena cava in liver disease (193,204). 
Recently McCuskey et al investigated the relative species sensitivity 
of E. Coli endotoxin in guinea pig, hamster, mouse and rat, and found a 
strong correlation between the sensitivity to endotoxins and the number 
of Kupffer cells. The guinea pigs, with the highest number of Kupffer 
cells, were very sensitive to endotoxins, whereas rats with the lowest 
number of Kupffer cells had the lowest sensitivity to endotoxins (205). 
These findings suggest that the Kupffer cells are not only the 
-principal site for the removal of circulating endotoxins but also the 
source of toxic mediators that participate in the host response to 
endotoxins. Endotoxins have direct hepatotoxic effects resulting in a 
diminished hepatic microcirculation, due to swelling of Kupffer and 
endothelial cells and the adhesion of leucocytes and platelets to the 
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sinusoidal walls, swelling and vacuolisation of hepatocytes with cell 
necrosis and cholestasis (215). 
There a_re at least four experimental models that show that endotoxins 
contribute to liver injury. In choline deficient rats the presence of 
intestinal bacteria was found to be crucial for the development of 
liver cirrhosis (216). The hepatic injury caused by CC14 , 
D-galactosamine and frog virus 3 can be prevented by pretreatment of 
the animals with either polymixin B, which disrupt the cell walls of 
gram negative bacteria and binds endotoxins or colectomy (216,217,218, 
219). Besides a direct hepatotoxic effect of endotoxins, liver disease 
is often associated with a diminished clearance of endotoxins resulting 
in enhanced systemic toxic effects, such as coagulation disorders, 
hypotension and renal failure (204). Several authors have described the 
presence of endotoxemia in liver disease (192,193,195,204). Van Vliet 
and co-workers found, for example, in 36% of the patients with acute 
hepatitis and in 46% of the patients with liver cirrhosis a positive 
Limulus amoebocyte lysate test. The patients with systemic endotoxemia 
had a lower platelet count, a more disturbed renal and liver function, 
and a higher mortality rate (193). These findings confirmed those of 
several other authors (195,204). 
Many studies have found a correlation between endotoxemia and impaired 
renal function in liver disease (183,184,195,204,220,221). The 
hepatorenal syndrome might be directly or indirectly due to systemic 
endotoxemia (184,204,214,220). In fulminant hepatic failure endotoxemia 
has been shown to be related to renal failure and intravascular 
coagulation (221). In patients with liver disease several immunological 
abnormalities including hypergammaglobulinemia, decreased delayed type 
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hypersensitivity and a disturbed function of monocytes have been found 
(193,222). In lipopolysaccharide stimulated monocytes derived from 
patients with liver disease increased interleukin I release was found 
suggesting that the immunoregulatory function of monocytes is dis-
ordered in liver disease (222). Systemic endotoxemia is found in patients 
with a diminished RES function. Acute and chronic ethanol administration 
impairs RES function. Within the fir9t 24 hours of acute alcohol 
intoxication, the clearance rate of micro aggregated human serum 
albumin was 1.5 to 2- fold less than in a healthy control group (223). 
Acute and chronic ethanol intoxication suppress DNA synthesis in the 
liver of rats resulting in inhibition of hepatic regeneration (224,225, 
226). The suppression of ethanol on he?atic regeneration can be 
prevented by pretreatment with 16,16 dimethyl prostaglandin E2 (226). 
Which again subscribe that NSAIDs must be used with caution in liver 
disease (175,226). 
Administration of ethanol results in histologic changes of the small 
intestine and enhanced permeability for several macromolecules by the 
gut (227 ,228). As endotoxins are macromolecules, ethanol might affect 
endotoxin absorption of the gut. However the permeability of the 
intestine to endotoxins is not increased after chronic administration 
of ethanol in the rat (227). In patients with liver disease intestinal 
bacterial overgrowth have been found, so an increased absorption of 
endotoxins from the gut is not ruled out (229,230,231). 
Recently Bode et al examined in aspirates from the jejunum of 27 
chronic alcoholics and 13 hospitalized control patients without liver 
disease the types and numbers of bacteria. In the alcoholic group they 
obtained significant more anaerobic and aerobic bacteria than in the 
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control group, suggesting that the bacterial overgrowt.h in alcoholics 
might contribute to functional and or morphological abnormalities of 
the small intestine and systemic endotoxemia (229). 
We recently confirmed these findings with the aid of breath test 
detecting bile acid deconjugation (232,233). In the presence of 
bacterial colonization of the small bowel, bile acids are deconjugated 
by anaerobic bacteria. The deconjugation of these bile acids can 
detected by means of a breath test. Bacteria in the bowel split off 
1-14c-glycine from (l-14c-glyco)cholic acid which is further broken 
14 down to co2 which can be measured in the expired air. In a number of 
small intestinal disorders characterized by stagnation or incomplete 
absorption of bile acids an abnormal breath test occurs. Patients with 
a bacterial overgrowth have a peak 14co2 excretion before 4 hours 
(234,235). We were interested if patients with liver cirrhosis had a 
disturbed breath test as a measure of bacterial overgrowth and examined 
7 patients with alcoholic liver cirrhosis. In five out of seven 
patients we found a late peak after 4 hours. As alcoholics have a 
diminished gastrointestinal motility (236), this peak might be due to 
bacterial overgrowth in these patients. 
3.4 ENDOTOXIN$ AND ENDOGENOUS MEDIATORS 
Interaction of endotoxins with macrophages results in the liberation of 
several mediators, such as procoagulant substances, collagenase, colony 
stimulating factors, complement components, lysozyme factors, 
substances cytotoxic or cytolytic for tumour cells, histamine and 
eicosanoids (192,196). One mediator released after endotoxin 
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administration is histamine~ which has been suggested to play a role in 
galactosamine induced liver cirrhosis by causing edema of the colon 
which promotes increased absorption of endotoxins (195). Indeed 
cime"tidine~ a R2 blocker protects against CC14 damage in rats 
(204,25, J. This protection is not necessarily an antihistamine effect 
of cimetidine but could be due to interference with cc14 metabolism. In 
a pilot study in collaboration with Dr. J. Keyser from Groningen we 
measured urine histamine metabolites (238) in ten patients with liver 
cirrhosis and found raised levels of methylhistamine in five out of ten 
patients (unpublished results). Further study on the role of histamine 
in the pathogenesis of the complications in liver cirrhosis are needed 
before conclusions can be drawn. 
There is increasing evidence that eicosanoids are involved in 
endotoxin-induced injury in several species (table II) (168~169~171, 
239,240,241). 
Table II. IN VITRO AND IN VIVO RELEASE OF EICOSANOIDS BY ENDOTOXINS 
PGE2 
PGF2alpha 
PGI2 
TXB2 
LTB4 
LTC4 
For example the endotoxin effects such as fever~ shock~ diffuse intra-
vascular coagulation~ renal failure~ adult respiratory distress 
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syndrome (ARDS), thrombocytopenia and leucopenia are all possibly 
mediated by eicosanoids. 
Endotoxin induced fever is the result of the effect of Interleukin I on 
eicosanoids production in the thermoregulatory center in the brain, 
where interleukin 1 initiates an abrupt increase in the synthesis of 
PGE2 in the anterior hypothalamus. PGE2 raise the thermostat set point 
in the hypothalamus. Besides the raised PGE2 production in the hypo-
thalamus, interleukin I induces a dramatic increase in PGE2 production 
in muscles (197 ,206). The beneficial effects of antipyretics on fever 
and associated myalgias are the result of blocking the cyclooxygenase 
pathway (197). 
After endotoxin administration raised levels of PGE2 , PGF 2alpha and 
especially TXB2 and 6 keto PGF1alpha are found and these are thought to 
be the most important mediators of the cyclooh-ygenase pathway in 
endotoxin shock (243). Endotoxins induce raised plasma TXB2 levels in 
several species including cats, mini pigs, baboons, rats and sheep 
(168, 169 ,240). Immediately after endotoxin administration there is a 
sharp rise in plasma TXB2 levels followed by a prolonged rise of 6 keto 
PGF 1alpha' PGFZalpha and PGE2 (243). Several NSAIDs such as indomethacin 
salicylate and ibuprofen improve hemodynamics and survival in experi-
mental endotoxin shock (240,243). The importance of TXB2 in endotoxin 
shock is sustained by the development of a selective TXA2 synthetase 
inhibitor, imidazole, which gives a 24 hour survival rate of 80% 
compared to 8% in the non treated group and lessened the severity of 
coagulapathies in endotoxin shock (168,172). Additional evidence, that 
prostaglandins are detrimental in endotoxic shock has been obtained in 
essential fatty acid deficient rats. These rats can only release small 
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amounts of prostaglandins derived from arachidonic acid and appear to 
be less susceptible to endotoxic shock, indicated by a markedly reduced 
mortality rate (243,241). 
Reines et al measured plasma TXB2 levels in twelve patients with septic 
shock. In eight patients dying with septic shock the plasma TXB2 levels 
were ten times higher than in the four survivors (170). Recently we 
measured plasma TXB2 levels in seven patients with gram negative septic 
shock. In six patients intermittently raised plasma TXB2 levels were 
found, which were associated with a more disturbed renal function (to 
be published). These studies raise the possibility that thromboxanes 
may be involved in the pathophysiology of sepsis. 
However Fletcher et al recently found that imidazole in contrast to the 
use of NSAIDs did not improve survival of rats with a gram negative 
sepsis even though thromboxane synthesis was inhibited (244). Their 
findings suggest that thromboxane mediates some events early in sepsis 
but is not important in the irreversibility of the shock state in this 
experiment. One possible explanation of the failure of imidazole in 
septic shock might be the involvement of leukotrienes. This hypothesis 
is sustained by the finding that endotoxic shock in rabbits results in 
raised levels of phospholipase~' which release the precursor AA, the 
substrate for PGs and LTs (245, and see section PLA2). 
The ARDS is a major complication in septic patients (197). Several 
investigations suggest that endotoxins play a major role in the 
pathophysiology of ARDS. In intaC't animals endotoxins provoke broncho 
constriction, pulmonary hypertension and increased pulmonary vascular 
permeability leading to edema and respiratory failure. Sequestration of 
leucocytes and platelets in the lung, as well as the generation of COP 
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have all been implicated as important factors in the lung injury. The 
endotoxin induced bronchoconstriction can be reversed by the use of 
cyclooxygenase blockers. The endotoxin induced lung vasoconstriction 
and platelet sequestration is mediated by throm.boxanes and can be 
abolished by selective TXA2 synthetase blockers (86,210,246,247). The 
increased vascular permeability leading to pulmonary edema can be 
abolished by high doses of corticosteroids, but not by NSAIDs or 
selective TXA2 synthetase blockers, suggesting that COP do not mediate 
the increase of vascular permeability after endotoxins (86,210). 
Leukotrienes c4 and n4 can increase pulmonary vascular resistance (see 
section lung and eicosanoids). Large increases of SHETE, approximatedly 
coincident with the onset of increased permeability in the lung 
indicate that lipoxygenase products, such as leukotrienes, could play a 
role in mediating the increased lung vascular permeability after 
endotoxin (86). 
The myocardial depressent factor, which reduces myocardial 
contractility, constricts the splanchnic arteries and impairs RES 
phagocytosis is elevated after endotoxin administration (213). The 
thromboxane synthetase inhibitor, imidazole, has been found to be 
effectively in preventing the formation of myocardial depressent factor 
in endotoxin shock (213). 
The induced adhesion of leucocytes to the vascular wall by endotoxins 
is probably due to leukotriene B4 production (102,215). 
Endotoxins inhibit the hepatobiliary elimination of leukotriene n4 and 
this might facilitate liver damage (248). The endotoxin induced 
hypoglycemia is, in part, mediated by PGE2 (249,250). 
Human and rat peritoneal macrophages and Kupffer cells produce a scala 
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of eicosanoids, such as PGE2 , TXB2, 6-keto-PGFlalpha' PGFZalpha' LTc4 , 
LTB4 and LTD4 , after incubation with calcium ionophore or endotoxins 
(68,69,156,157,251,252). 
In conclusion several biological effects of endotoxins are mediated by 
eicosanoids and can be prevented by using blockers of the eicosanoids 
pathway. The deleterious effect of endotoxemia in liver disease, such 
as diffuse intravascular coagulation, hypotension, renal failure, 
hepatorenal syndrome, leucopenia, fever, high mortality rate and liver 
damage might be mediated by eicosanoids. 
References: see page 163. 
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CHAPTER 4 
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4.1 ABSTRACT 
In experimental animals endotoxin administration causes increased 
levels of thromboxane B2 and prostaglandins. Liver cirrhosis is often 
complicated by endotoxem.ia. In sixteen patients with alcoholic liver 
cirrhosis, we measured plasma thromboxane B2 levels. In twelve patients 
we found on one or more occasions rais~1 plasma thromboxane B2 levels. 
Raised plasma thromboxane B2 levels were associated with significantly 
higher serum levels of urea, alkaline phosphatase, gamma glutamyl 
transpeptidase and lower antiplasmin and antithrombin III levels. It is 
possible that some of the complications in patients with alcoholic 
liver cirrhosis are mediated by thromboxane~. 
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4.2 INTRODUCTION 
Endotoxins are bacterial cell wall lipopolysaccharides of gram negative 
bacteria (l). Administration of endotoxins to experimental animals 
results in raised plasma thromboxane B2 (TXB2), the stable metabolite 
of thromboxane A2 , levels (2) and is associated with shock, decreased 
renal blood flow, pulmonary hypertension and a high mortality rate 
(3,4,5). Some of these effects of endotoxin administration can be 
blocked by pretreating the animals with a thromhoxane A2 (TXA2) 
synthetase inhibitor (6,7,8). 
Severe liver disease is associated with a high frequency of endotoxemia 
(9, 10). The circulatory and laboratory changes seen in these patients 
(11,12) are similar to the effect of I~. We therefore measured plasma 
levels of TXB2 in sixteen patients with liver cirrhosis to determine 
whether raised plasma TXB2 levels were associated with other 
complications. 
4.3 PATIENTS AND METHODS 
Sixteen patients with alcoholic liver cirrhosis (14 men~ 2 women~ aged 
31-76 yrs) were studied. One or more of the following complications 
were present: ascites~ jaundice, encephalopathy and bleeding 
oesophageal varices. 
On two or more occasions peripheral venous blood samples (10 ml) were 
collected under resting conditions in polypropylene tubes containing 20 
ul of heparin (5000 U/ml, ThromboliquineR, Organon, Oss, The 
Netherlands) and 50 ul indomethacin (0,1 mg/ml in 0.1 M phosphate 
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buffer pH 8). 
At the same time blood was taken for liver and renal function tests~ 
R platelet count, Normotest (a measure of the levels of clotting factor 
II., VII, X (Nyegaard Pharmacie B. V., Haarlem, The Netherlands))~ 
antithrombin III~ antiplasmin and fibrinogen levels. Normal values for 
plasma TXB2 levels were obtained from blood samples taken from 17 
controls (aged 22-78 yrs) on two occasions. The controls did not have a 
history of liver disease and had not received non-steroidal anti 
inflammatory drugs (NSAIDs) or corticosteroids during the previous 
month. 
The blood samples taken for plasma TXB2 determination were centrifuged 
immediately at 1409 g for 10 mins and the plasma stored at -20°C until 
assay. Two ml of plasma was applied to a Sep-pak c18R cartridge (Waters 
Ass. Inc., The Netherlands) which had previously been washed with 10 ml 
of absolute ethanol and 10 ml of distilled water. 
The column was rinsed with 2 m.l of distilled water and the 
prostaglandin-like compounds eluted with 2 m1 of absolute ethanol. 200 
ul aliquots were dried under a stream of nitrogen at 40°C in a 
radioilnmunoassay tube and redissolved in assay buffer. Radioimmuno 
assay kits were obtained from New England Nuclear. 
Statistical analysis: Results of laboratory tests at different times in 
the same patient were compared by the paired two-tailed Wilcoxon test. 
4.4 RESULTS 
In twelve of sixteen patients with alcoholic liver cirrhosis we found 
raised plasma TXB2 levels (200-1000 pg/ml) on one or more occasions. 
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Table I. Plasma thromboxane B2 levels in relation to some other 
laboratory findings in patients with liver cirrhosis. 
group 1 group 2 
laboratory test normal value (4) (12) 
TXB2 always during normal during raised 
normal TXB2 period TXB2 period 
----------------------------------------
platelet count 109/1 120 - 320 151 ! 40 128 ! 18 140 ! 26 
serum creatinin umol/1 60 110 83 ! 8 85 ! 7 90 ! 8 
serum urea mmol/1 2,5 - 8,0 6,0 ! 1,0 6,6 ! 1,0 8,0 ! 2,0* 
serum alk.phosph U/1 18 - 45 48 ! 8 58 ! 10 71 ± 10* 
serum g.g.t. U/1 5 25 86 ± 23 68 ! 15 95 ! 24** 
plasma Normotest % 65 110 59 ! 7 49 ± 7 44 
" 
5 
plasma antithrombin III 80 - 120 63 ! 5 60 
" 
7 50 ! 8** 
plasma antiplasmin % 85 - 120 72 ! 5 69 ! 6 59 ! 7** 
The laboratory findings are given as meam: SEM- The platelet count, 
serum creatinin, urea, alkaline phosphatase (alk. phosph.) and gamma 
glutamyl trans-peptidase (g.g.t) are expressed in Sl units, the levels 
of clotting factors as a percentage of a normal standard. The results 
of the laboratory tests in patients in group 2 during periods with raised 
plasma TXB levels ( <.200 pg/ml) are compared with results during 
periods wit~ normal TXB2 levels by the paired two-tailed Wilcoxon test (* p<0,01, ** p<0,05). 
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The mean plasma TXB2 level in 17 healthy individuals was 118 pg/ml 
(range 25-190). 
Raised plasma TXB2 levels were associated with a disturbed renal 
function as measured by the serum urea level, a disturbed liver 
function as measured by raised plasma alkaline phosphatase and gamma 
glutamyl transpeptidase level and disturbed clotting mechanis~ as 
measured by lower antiplasmin and antithrombin III levels, compared to 
the values obtained by the same twelve patients at times when plasma 
TXB2 levels were normal (table I). There were no significant 
differences in platelet count, leucocyte count and fibrinogen levels 
between the periods of raised and normal plasma TXB2 levels. In the 
four patient.s with repeatedly normal plas~ TXB2 levels mean platelet 
count, mean renal function and liver function tests and mean clotting 
factors were less abnormal than in the patients with raised plasma TXB2 
levels. 
Two patients with raised plasma TXB2 levels died, one after two and one 
after eight days. All four patients with normal plasma TXB2 levels 
survived. The mean duration of hospitalisation in the group with raised 
plasma TXB2 levels was 33 days (range 2-66), compared to sixteen days 
in the group with normal plasma TXB2 levels. 
4.5 DISCUSSION 
In this study we have shown that twelve out of sixteen patients with 
complicated alcoholic liver cirrhosis had raised plasma TXB2 levels. 
Recently Zipser reported increased urinary TXB2 levels in patients with 
the hepatorenal syndrome (13), which is in agreement with our findings. 
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The raised plasma TXB2 levels are associated with changes in plasma 
concentration of clotting factors and deterioration of liver and renal 
function tests, features which we have previously shown to be 
correlate4 with endotoxemia in such patients (11). 
TXB2 is a stable metabolite of TXA2 , which is a potent platelet 
aggregating and vasoactive substance (2). The raised plasma TXB2 levels 
in these patients are probably due to increased production of TXA2• 
Thromboxanes have been proposed as mediators of some endotoxin effects. 
Thus the increased plasma TXB2 levels are possibly an effect of 
endotoxemia in these patients. 
In experimental animals NSAIDs and corticosteroids, which block the 
production of prostaglandins, diminish the effects of endotoxin 
administration (14-18). In mice with multiple liver granulomas 
extensive liver parenchymal cell damage following endotoxin 
administration could be prevented by pretreatment with NSAIDs or 
corticosteroids (19). In rats there is a marked elevation of plasma 
TXB2 levels after intravenous administration of endotoxins (3,6). 
Pretreatment of these animals with a TXA2 synthetase inhibitor gives a 
24 hour survival rate of 80% compared to 8% in the non-pretreated group 
(6). NSAIDs are also effective in several diseases with raised 
prostaglandin levels, such as rheumatoid arthritis (20,21), Barrter's 
syndrome (22) and systemic mastocytosis (23). 
Although it seems reasonable to suggest a trial of NSAIDs in cirrhosis, 
the administration of such drugs to patients with liver cirrhosis, 
especially those with ascites, has been shown to cause renal failure 
(24,25) and treatment of patients with low levels of clotting factors, 
as in liver cirrhosis, may give rise to bleeding problems (26). 
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Some authors have found raised plasma prostaglandin E (PGE) levels in 
the hepatorenal syndrome (27) and elevated urinary PGE2 levels in liver 
cirrhosis with ascites (28) and suggested that the raised PGE levels 
play .a supportive role in maintaining renal function in patients Yith 
liver disease (28). Others have found a relationship between urinary 
prostaglandins E2 and F2alpha and sodium excretion in various stages of 
chronic liver disease (29). The proposed beneficial effect of 
prostaglandins on renal blood flow in cirrhosis provides an explanation 
for the deterioration of renal function after NSAIDs administration in 
patients with severe liver disease. 
Thus although we tentatively conclude that some of the complications of 
cirrhosis may be mediated by thromboxanes, the clinical experience with 
NSAID suggests that some of the other arachidonic acid metabolites have 
a beneficial function in these patients. As NSAID block the enzyme 
cyclooxygenase, they reduce the formation not only of thromboxanes, but 
also of the beneficially-acting prostaglandins. The recent development 
of specific thromboxane synthetase blockers (30,31) has potential value 
as a means of determining the role of thromboxane in the complications 
of liver cirrhosis. 
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CHAPTER 5 
SITES OF THROMBOXANE B2 PRODUCTION AND REMOVAL IN LIVER CIRRHOSIS. 
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Vincent, Ivan L. Bonta, Marcel van den Brand, Patrick Serruys, Harry 
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5. 1 ABSTRACT 
In patients with alcoholic liver cirrhosis raised plasma thromboxane B2 
levels are found. Ihromboxane B2 is the stable metabolite of 
thromboxane A2 , a· potent vasoconstrictor. To determine the site of 
production and removal of thromboxane B2 and to investigate the 
hemodynamic consequences of raised plasma thromboxane B2 levels :o we 
measured plasma thromboxane B2 levels during hepatic vein 
catheterisation in 3 patients with alcoholic cirrhosis and 2 patients 
with cryptogenic liver cirrhosis. In four patients there was a net 
thromboxane B2 production by the splanchnic area and in all patients 
there was a removal of thromboxane B2 by the lungs and kidneys. 
Following dazoxiben, a thromboxane synthetase blocker, thromboxane B2 
levels fell by 50-70% from their original value. The fall of 
thromboxane B2 levels was not associated with consistent changes in 
systemic and pulmonary pressures, cardiac index~ hepatic vein pressures 
or hepatic blood flow. The extraction fraction of indocyanine green 
decreased after dazoxiben; probably due to interference of indocyanine 
green uptake by the liver by dazoxiben. The lack of circulatory changes 
following a decrease in throm.boxane levels suggests that the raised 
plasma thromboxane B2 levels in cirrhosis might be a secondary 
phenomenon. 
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5.2 INTRODUCTION 
Prostaglandins and other arachidonat.e metabolites may be involved in 
the circulatory changes in liver cirrhosis. Prostaglandins, especially 
prostaglandin E2 , are thought to play a role in maintaining renal 
function in cirrhosis (1-7); non-steroidal anti-inflammatory drugs 
which block prostaglandin synthesis have been shown to reduce renal 
blood flow (1,7) and block the effects of furosemide in cirrhotics 
(4,5, 7). Other arachidonate metabolites which have received attention 
as possible vasoactive mediators of the circulatory changes in liver 
disease are thromboxane and prostacyclin. Recently Hamilton et al (8) 
found an increased production of prostacyclin (PGI2) in the portal vein 
in experimental portal hypertension. These workers postulated that 
PGI2 , which is a vasodilator, might be involved in the development of a 
collateral circulation. 
Thromboxane A2 , a potent vasoconstrictor and platelet aggregant, is 
rapidly metabolised to the stable compound, thromhoxane B2 (TXB2) (9). 
We recently showed that plasma TXB2 levels are intermittently raised in 
patients with alcoholic liver disease (10). The levels of TXB2 found in 
these patients were similar to levels shown to be associated with 
vasoconstriction in rabbits (11,12). The raised TXB2 levels were 
associated with higher levels of serum urea and a more disturbed liver 
function as measured by an increase in alkaline phosphatase and gamma 
glutamyl transpeptidase and a decrease in antiplasmin and antithrombin 
III levels. Raised urinary TXB2 levels have also been described in 
patients with the hepatorenal syndrome (6). These findings suggest that 
in addition to the possible beneficial effects of prostaglandins in 
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liver disease, another arachidonate metabolite - thromboxane A2 - might 
be contributing to the complications of liver cirrhosis. 
In order to determine the site of thromboxane production in liver 
cirrhosis, we measured hepatic venous TXB2 levels during hepatic vein 
catheterisation. The catheterisation permitted sampling in both right 
atrium and renal vein, which meant that we could also determine the 
site of TXB2 elimination. In an attempt to study the hemod~c 
effects of the raised thromboxane levels, we administered dazoxiben, a 
specific thromboxane synthetase blocker, during the catheterisation 
procedure and followed the changes in TXB2 levels and various 
parameters of the systemic, pulmonary and portal circulation. 
5.3 PATIENTS AND METHODS 
Five consecutive patients with cirrhosis of the liver in whom hepatic 
vein catheterisation was to be performed as part of the diagnostic 
work-up of portal hypertension were asked to participate in the study. 
The aims and procedures of the study were explained to the patients, 
who all gave informed consent. The protocol was approved by the medical 
ethics committee of the University Hospital-Rotterdam. Three of the 
patients had an alcoholic cirrhosis, the other two had a cryptogenic 
cirrhosis. The diagnosis of cirrhosis was based in all patients on 
laparoscopy and liver biopsy. Parenchymal liver function was assessed 
by serum albumin, bilirubin and Normotest (Nyegaard, Oslo, Norway), 
which is a measure of the clotting factors II, VII, IX and X. Serum 
creatinine was used as a measure of renal function (Table I). 
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Table L Clinical and biochemical characteristics of five patients 
undergoing catheterisation. 
Patient no. 1 2 3 4 5 
Cirrhosis Ale Ale Ale Crypt Crypt 
-----------------------------------------------------------------------
Age (yr) 61 57 60 59 79 
Sex M M F M F 
BW (kg) 84 87 67 65 56 
Ascites + + + + 
Bilirubin (mg/ dl) 2.6 2.4 0.58 0.7 0.7 
Normotest. (%) 35 37 74 72 96 
Albumin (g/1) 24 27 40 32 39 
Creatinine (mg/ dl) 0.9 1.0 1.0 0.9 1.0 
Right sided heart catheterisation was performed via the femoral vein by 
the Seldinger technique, using a Swan-Ganz thermodilution catheter. 
Pressures were measured by a strain gauge transducer and cardiac index 
by thermodilution in triplicate. Pressures were measured in the right 
atrium (RA), pulmonary artery in free (PA) and wedged (PCW) position 
and hepatic vein in free (FHV) and wedged (WHV) position and are 
expressed in mmHg as mean value of the triplicate observations. The 
WHVP was confirmed by monitoring the pressure during expansion of the 
catheter balloon and by the absence of reflux of injected contrast 
medium. The hepatic venous pressure gradient is the WHVP minus the FHVP. 
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Arterial pressures were monitored by a strain gauge transducer via a 
catheter in the femoral artery. Another catheter was placed in the 
renal vein to allow blood sampling. Renal vein catheterisation was not 
performed in patient 4 due to technical difficulties. 
Estimated hepatic blood flow was determined by the indocyanine green 
(ICG) continuous infusion method (13). Blood was taken from the RA, 
renal vein (RV), hepatic vein (HV) and artery (A) for determination of 
N .. -ygen saturation (Sa02) and plasma TXB2 levels. The initial 3 ml of 
blood was discarded, 3 ml of blood was collected in a 3 ml plastic 
syringe containing 20 ul of heparin (Thromboliquine 5000 U/ml, Organon, 
Oss, The Netherlands) and the Sa02 were measured immediately. Blood for 
plasma TXB 2 was collected in polypropylene . tubes containing 20 ul of 
heparin (5000 U/ml) and 50 ul of indomethacin (0 .1 mg/ml in 0.1 M 
phosphate buffer pH 8.0). The plasma TXB2 was measured by RIA, after 
applying the plasma to a Sep-Pak c18 (R) cartridge (Waters Ass. Inc. The 
3 Netherlands) (10). The overall recovery of ( H) TXB2 added to plasma 
was 85-90%, and the purity of the sample was found to be greater than 
95% on HPLC. The cross reactivity of the TXB2 antibody with other 
prostaglandins was as follows: TXB2 100%, prostaglandin E2 0.2%, 
prostaglandin A2 0. 2%, prostaglandin F2 0. 2% and 6-keto-PGF !alpha 
0.2%. Normal values for plasma TXB2 levels, < 200 pg/ml, were taken 
from our previously described study (10). Blood was taken from the 
various sites within 60 seconds by rapidly moving the catheter from HV 
to RA. Systemic vascular resistance and pulmonary vascular resistance 
(expressed per m2 body surface area) were calculated from the mean 
arterial or pulmonary arterial pressures and the cardiac index. After 
baseline measurements at 0 and 15 minutes, the patients were given 100 
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mg of dazoxiben as a bolus injection intravenously and the hemodynamic 
measurements and blood sampling performed 15, 30 and 45 minutes later. 
Net uptake or release of TXB2 by the splanchnic area, kidneys or lungs 
was demonstrated by comparing HV, RV or RA TXB2 levels with arterial 
TXB2 levels. We made an estimate of TXB2 production in the splanchnic 
area, before the administration of dazoxiben, by multiplying the net 
HV-A difference by t.he estimated hepatic blood flow. In a similar 
fashion we calculated net pulmonary TXB2 uptake, before dazoxiben, by 
multiplying the RA-A difference by the cardiac output. 
5.4 RESULTS 
All patients had portal hypertension as judged by a raised hepatic 
venous pressure gradient (HVPG) (Table II). The normal HVPG using this 
method is 4 mm.Hg (14). Before administration of dazoxiben the three 
patients with alcoholic liver cirrhosis had raised plasma TXB2 levels 
in RA, HV and A, as opposed to the two patients with cryptogenic 
cirrhosis, although one of these had a plasma TXB2 level at the upper 
limit of the normal range (Table III). Before the administration of 
dazoxiben there was evidence of a net TXB2 production in the splanchnic 
area in four patients (Table IV), the exception being the patient with 
cryptogenic cirrhosis and the lowest initial TXB2 level. Total TXB2 
production in the splanchnic area was high in the alcoholic cirrhotics. 
Before dazoxiben there was a positive RA-A and A-RV, difference of 
plasma TXB2 levels (Table IV), suggesting that the kidneys and lungs 
eliminate TXB2 from plasma. Following the administration of dazoxiben 
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Table II, Values expressed as mean pressures before (pre) and the mean value of the pressures measured 
at 15 1 , 30 1 , 45' after dazoxiben (post) intravenously in patients with cirrhosis, 
Patient no, 2 3 4 5 
pre post pre post pre post pre post pre post 
------------------------------------------------------------------------------------------------------
Right atrium, mroHg 2 3 7 7 2 1 0 7 0 0 
A, Pulmonalia, mmHg 11 14 15 14 18 16 9 14 11 12 
Wedge pulmonalia, mroHg 10 9 11 10 7 5 3 5 6 6 
Artery, mmHg 71 71 78 70 114 110 112 113 71 73 
Heart rate, min 85 92 80 79 79 83 86 82 68 68 
Cardiac index, l/min/H 2 4.3 3.98 5.58 5.26 3.4 3.68 3.65 4.17 3.16 3.13 
SVR, 5 dyne,sec/cm .M2 1282 1014 966 993 2632 2334 2452 2031 1795 1867 
PVR, 5 dyne,sec/cm ,H 2 18.6 106 57 61 258 225 131 178 126 140 
Hepatic vein free, mmHg 9 9 10 10 4 4 9 8 1 3 
Wedge hepatic, mmHg 19 19 31+ 35 20 20 25 23 14 14 
HVPG, mmHg 10 10 24 25 16 16 16 15 13 11 
------------------------------------------------------------------------------------------------------
SVR = systemic vascular resistance 
PVR = pulmonary vascular resistance 
HVPG =hepatic venous pressure gradient. 
"' <.n 
Table III. Plasma TXB2 levels (pg/ml) before (pre) and 15
1
, 30' and 45' after (post) dazoxiben. 
Patient no. 2 3 4 5 
pre post pre post pre post pre post pre post 
Hepatic vein 656 125 611 161 410 142 192 85 106 59 
Right atrium 585 116 413 167 325 186 183 85 129 67 
Artery 368 143 328 165 250 170 162 64 115 99 
Renal vein 190 104 190 127 187 144 a a 71 64 
- -
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not measured due to technical difficulties. 
Table IV. Arterio-venous differences in TXB2 concentrations and 
calculated net TXB2 production by the liver and net TXB2 
removal by the lung. 
Patient l 2 3 4 
HV - A 288 283 160 30 
RA- A 217 85 75 21 
A RV 178 138 63 a -
TXB2 production 173 131 128 17 
by liver.ng/min. 
TXB2 elimination 1801 995 435 128 
by lung. ng/min. 
a RV samples not measured due to technical difficulties. 
Table V. Estimated hepatic blood flow (EHBF), ml/min and extraction 
fraction (EF) of indocyanine green before (pre) and after 
(post) dazoxiben. 
EHBF (llll/min) EF (%) 
pre post pre post 
Patient l 601 603 38 29 
Patient 2 463 928 27 20 
Patient 3 799 727 51 46 
Patient 4 565 571 37 32 
Patient 5 1081 895 43 39 
86 
5 
-9 
14 
44 
0 
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plasma TXB2 levels dropped in all patients (Table III). Mean plasma 
TXB2 levels in hepatic vein from all patients dropped after 15' to 58% 
(range 23-78), at 30' to 72% (range 44-84%) and at 45' to 59% (range 
40-80%) from the original values. In figure 1 the changes in plasma 
TXB2 levels in patient 2 after the intravenous administration of 100 mg 
dazoxiben are shown. 
pg/ml 
400 
200 
0 
0 
t 
15 
hepatic vein 
right atrium 
artery 
30 
min 
45 
Fig. 1. Plasma TXB2 levels (pg/ml) before (0) and 15-, 30-, and 45 min. 
after administration of dazoxiben 100 mg intravenously in 
patient 2. 
Following the injection of dazoxiben no significant changes occurred in 
RA, PA, PCW, FHV, WHV or A pressures (Table II). No consistent changes 
were seen in cardiac index, systemic or pulmonary vascular resistance 
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after dazoxiben (Table II). Estimated hepatic blood flow (EBBF) did not 
change after dazoxiben (Table V). In all patients, however, the 
extraction fraction of ICG by the liver declined after dazoxiben 
administration (Table V). 
There were no significant changes in Sa02 after dazoxiben in RA, HV, 
RV, A. 
5.5 DISCUSSION 
Raised peripheral plasma TXB2 levels were found in the three patients 
with alcoholic liver cirrhosis. This is in agreement with our previous 
findings (10). In four of five patients with cirrhosis we found the 
highest TXB2 levels in hepatic vein, which points to a net production 
of TXB2 by the splanchnic area, possibly by the liver. The patient 
without a net TXB2 production had a compensated cryptogenic liver 
cirrhosis with the best liver function and the highest EHBF of all 
patients (Table I, Table V). The origin of the TXB2 in the splanchnic 
area is uncertain. Chong et aL (15) found TXB2 synthesis by isolated 
hamster hepatocytes after exposure to vasopressin, demonstrating that 
hepatocytes are capable of producing TXB2• Kupffer cells are a possible 
alternative source for the TXB2 production. 
The splanchnic area is not the only site of increased production of 
TXB2 in liver cirrhosis, the calculated net production rates of TXB2 by 
the splanchnic area being lower than the calculated net removal rate of 
TXB2 by the lungs. As we did not measure renal blood flow it was not 
possible to calculate the relative contribution of the kidney to the 
removal of TXB2 from the plasma. 
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The pathophysiologic implications of the raised plasma TXB2 levels and 
increased production rates in alcoholic liver cirrhosis are still not 
clear. 
Recently Zipser et al. found raised urinary TXB2 and lower PGE2 levels 
in cirrhotics with the hepatorenal syndrome but not in patients with 
cirrhosis and normal renal function. PlaSma TXB2 levels were however 
not measured in this study (6). 
In our investigation the decrease in plasma TXB2 induced by dazoxiben, 
a thromboxane synthetase blocker (16, 17), was not followed by changes 
in systemic, pulmonary or portal pressures and was not associated with 
changes in cardiac index or EHBF. In a small number of patients with 
the hepatorenal syndrome given either 400 mg or 600 mg of dazoxiben 
daily for four days Zipser et al (Zipser et al, Clinical Research 
32:288A,1984, abstract) observed a mean reduction in urinary TXB2 by 
54%, however without consistent improvement of renal function. 
One possible explanation for the failure of TXB2 blockade to result in 
hemodynamic changes in patients with liver cirrhosis is that the raised 
plasma TXB2 levels in these patients are a secondary phenomenon. 
Leukotrienes are candidates as stimulators of TXA2 production. 
Leukotrienes are arachidonic acid products of the 5 lipoxygenase 
pathway (18). Leukotrienes C4 and D4 are potent bronchoconstrictors 
(19) and cause a short lived vasoconstriction followed by extravasation 
of macromolecules (20). Leukotrienes have been shown to stimulate the 
release of TXA2 in vitro and in vivo (21,22). Recently Rosenthal et al. 
found that leukotrienes C4 and D4 gave a potent vasoconstriction of the 
isolated perfused rat kidney, which could be blocked by a specific 
blocker of the leukotriene synthesis (FPL 55712) but not by a specific 
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blocker of thromboxane synthesis (23). 
An interesting finding was that although the EHBF did not change, in 
all patients the EF for ICG decreased after administration of dazoxiben 
(Table V). The decrease in EF could be due to increased transhepatic 
shunting of blood, but this does not seem likely as we did not find 
changes in Sa02 in hepatic venous blood after dazoxiben. Another 
possibility is that dazoxiben interferes with ICG uptake by the liver. 
Dazoxiben contains an imidazole ring, as does cimetidine (16,24). The 
administration of cimetidine results in a lowered extraction fraction 
of ICG, probably due to interference of cimetidine "With the uptake of 
ICG by the liver (Jackson EJ. N Eng J Med 335:99,1981, correspondence, 
25). 
In conclusion, the raised plasma TXB2 levels found in alcoholic 
cirrhosis are in part derived from a net production in the splanchnic 
area. TXB2 is removed from the circulation by the lungs and the 
kidneys. Dazoxiben causes an acute drop in TXB2 production and in 
plasma TXB2 levels, but this is not associated with hemodynamic 
changes, suggesting that thromboxanes do not play an important role in 
the circulatory complications of liver cirrhosis. Further studies on 
other arachidonic metabolites, especially leukotrienes, are needed to 
unravel the cause of the overproduction of TXB2 in liver cirrhosis. 
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6 .1 ABSTRACT 
Endotoxins are thought to be responsible for a number of manifestations 
of gram negative sepsis and for several complications of liver disease. 
In experimental animals the administration of endotoxins results in 
raised levels of thromboxanes. Raised plasma thromboxane levels have 
been found in patients with liver cirrhosis and patients with sepsis. 
We performed a study to determine if there was a correlation betveen 
endotoxin levels measured by a Limulus Lysate assay with the aid of a 
chromogenic substrate and plasma thromboxane B2 levels. The study Yas 
performed in 6 patients with a gram negative sepsis and 12 patients 
with decompensated alcoholic liver cirrhosis. In only 3 of the 6 
patients with sepsis and in 8 of the 12 patients with cirrhosis did we 
find endotoxin levels above the upper limit of normal for the assay of 
12 pg/ml. In agreement with earlier work plasma TXB2 levels were raised 
in these patients. There was no correlation between endotoxin and 
thromboxane B2 levels. The lack of correlation could in part be 
ascribed to a considerable variability in the Limulus Lysate 
chromogenic assay. 
We conclude that the Limulus Lysate assay for endotoxin using a 
chromogenic substrate, as performed in this study, is unsuitable for 
clinical research due to variability of the standard curves and the 
lack of sensitivity of the assay. More reliable and more sensitive 
diagnostic tools for endotoxins are needed to evaluate the role of 
endotoxins in patients with liver disease or with sepsis. 
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6.2 INTRODUCTION 
Endotoxins from gram-negative bacteria play an important role in the 
manifestations of gram-negative sepsis and probably liver disease 
(1,2). The gut is a large reservoir of endotoxin producing 
gram-negative bacteria (2,3). In the normal state absorbed endotoxins 
are rapidly removed from the portal blood by the Reticula Endothelial 
System (RES), especially by the Kupffer cells (2). Detection of 
endotoxins was originally based on their in-vivo effects, e.g. 
pyrogenic effects in rabbits injected with the material to be tested 
(4). 
After a more detailed chemical survey of the active component of 
endotoxins it became clear that lipid A is responsible for the in-vivo 
reactions (5). This resulted in a search for a more sensitive and 
simpler analysis. At that time a very remote but interesting biological 
observation concerning the life cycle of the horseshoe crab revealed a 
clue for possible analysis (6, 7). Horseshow crabs frequently die in 
shallow water due to gram-negative sepsis and intravasal coagulation. 
This led Levin and Bang to the idea of using the amebocytes of this 
crab for a clotting gelation test for the determination of endotoxins 
(7). This test subsequently was used for clinical work (2,3,8). 
Various modifications and additions to this principle have been 
developed. The major one is the use of the "artificial" chromogenic 
substrates measuring peptidase activity giving not only a qualitative 
but also a quantitative result in the presence of endotoxins (9,10). 
Several authors have described the presence of endotoxemia in liver 
disease and sepsis (1,2,3,8,11). In the past we found a positive 
9.7 
Limulus amebocyte lysate (LAL) gelation test in 46% of patients with 
liver cirrhosis (8). 
In experimental animals endotoxin administration results in raised 
levels of several prostaglandins. Especially thromboxane B2 (TXB2) and 
6 keto-PGF 1alpha. are thought to be the most important prostaglandins 
playing a role in endotoxin shock (12~13~14). In patients with sepsis 
and liver disease raised plasma thromboxane B2 levels have been found 
(14~15). It is thought that the raised plasma TXB2 levels are due to 
endotoxemia in these patients. 
The aim of our study was to investigate the correlation between 
endotoxemia, measured by the generally accepted endotoxin assay with 
the aid of a chromogenic substrate S2423 (Kabi Vitrum, Amsterdam, The 
Netherlands) and the plasma TXB2 levels as measured by radioimmuno 
assay (RIA). 
6.3 PATIENTS AND METHODS 
Twelve patients with alcoholic liver cirrhosis (8 men, 4 women), age 
40-76 yrs~ and six patients (2 men, 4 women), age 29-70 yrs, with a 
gram-negative septicaemia proven by positive blood cultures were 
studied. All patients with sepsis had a systolic pressure below 100 
mmHg and renal dysfunction. Four patients had a positive blood culture 
with either Pseudomonas Aeraginosa, Klebsiella, Enterococcus and 
Escherichia Coli. Two patients had Bacillus anitratum and Bacteriodes 
in their blood cultures. Venous blood samples were collected on one or 
more occasions. 
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For the endo~oxin determinations 5 ml blood was taken by venepuncture 
with a pyrogen-free needle and syringe containing 50 ul of heparin 
(5000 IU/ml, ThromboliquineR, Organon, Oss, The Netherlands). The blood 
was immediately transferred to a pyrogen-free plastic tube on ice and 
centrifuged at 1200 xg for 10 mins. The plasma was stored in 
pyrogen-free plastic tubes at -20°C until assay. Immediately after 
blood sampling for endotoxin assay blood samples (10 ml) were collected 
for TXB2 assay in polypropylene tubes containing 20 ul of heparin (5000 
IU/ml ThromboliquineR, Organon, Oss, The Netherlands) and 50 ul 
indomethacin (0.1 ng/ml in 0.1 mM phosphate.buffer pH 8). 
Blood samples for plasma TXB2 determination were centrifuged 
immediately at 1400 g for 10 mins and the plasma stored at -20°C until 
assay. 
Endotoxins in plasma were measured according to the method described by 
Thomas et al (9,10). Some adjustments and modifications have since been 
made to optimize the results. These will be mentioned when appropriate. 
The heparin solution for blood collection was tested for endotoxin 
contamination. Plasma samples were diluted 10 times with pyrogen-free 
water and heated for 10 mins at 75°C. A plasma pool was constituted 
from twenty plasma batches to serve as reference plasma pool. The 
endotoxin assays were carried out generally according to the procedure 
suggested by the company. The exact procedure is as follows. A standard 
curve with known endotoxin concentration was constructed as follows. 
The endotoxin standard (2 ng) was solubilished in 1,0 ml of water and 
mixed vigorously for 3 mins. The endotoxin stock solution was diluted 
twenty times. The standard curve was made according to the instruction 
of the company. These standards were inactivated for 10 mins at 75°C 
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and left to cool. The LAL was solubilished in the appropriate amounts 
of water. Of the test sample or standard (both heat inactivated) 50 ul 
was equilibrated for 3-5 mins at 37°C~ mixed with 50 ul L.AL and 
incubated at 37°C for 20 mins. To the mixture 100 ul of the substrate 
buffer solution containing 1.1 mM S2423 (Kabi Vitrum., Amsterdam, The 
Netherlands) in 2,5 mM Tris pH 9 was added. After 10 mins the reaction 
was stopped by the addition of 400 ul of 50% acetic acid. A blank was 
made of every plasma sample. The extinction was read at 405 nm. A 
calibration line was constructed and unknown samples were calculated 
using this line. Plasma TXB2 levels were measured by RIA as described 
earlier (15). 
6.4 RESULTS 
The reproducibility of the endotoxin assay was investigated by making a 
set of calibration lines using twenty individually plasma samples and a 
single endotoxin stock standard. The resulting calibration lines varied 
considerably from 5.1 to 10.1 (n = 20). 
Values for endotoxin levels in eighteen healthy controls were found to 
be 6,3 ~ 2,8 pg/ml (mean z SD) and for TXB2 a median level of 70 pg/ml 
(range 25-225). 
In the 69 plasma samples of the twelve patients with liver cirrhosis we 
found an endotoxin level of 10,2 ~ 4,2 pg/ml (mean ~ SD) and for TXB2 a 
median value of 228 pg/ml (range 55 to 1521) (fig.l). Eight of the 
twelve patients Yith liver cirrhosis had intermittently endotoxin 
levels above 12 pg/ml. There Yas no correlation between plasma 
endotoxin and TXB2 levels. 
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In six patients with sepsis the endotoxin and respectively TXB2 levels 
were 8. 9 :!:. 4.4 pg/ml (mean :!:. SD) and 326 pg/m.l (median; range 60 to 
1386) (fig.!). Only three of the patients had on one or more occasions 
an endotoxin level above 12 pg/ml. 
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Fig.!. Plasma TXB2 levels on one or more occasions in controls (A), 
septic patients (B) and cirrhotics (C). 
Points on the same vertical line represent the same patient. 
6. 5 DISCUSSION 
In eight of the twelve patients with liver cirrhosis and in three of 
the six patients with sepsis we found endotoxin levels above 95% 
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confidence limit for normals of 12 pg/ml. One possible explanation of 
the negative results in septic patients might be due that blood 
cultures become positive when less than 100 microorganism per ml are 
present, whereas a positive LAL test requires more than 1000 
microorganism per· ml (16,17). As is in agreement with earlier work we 
found raised plasma TXB2 levels in patients with liver cirrhosis and 
sepsis (14,15,18). There was however no correlation between endotoxin 
levels and thromboxane B2 • This might be due to the failure of the 
limulus assay to detect endotoxemia even at levels giving symptoms - as 
was the case in the septic patients, to a lack of sensitivity of the 
assay - i.e. an overlap between endotoxemic patients and healthy 
controls, or to time related factors. 
The variability of the standard curves of the endotoxin assay and the 
poor sensitivity makes this test unsuitable for clinical research. 
Despite the poor results of this test we do think that endotoxins play 
a role in liver disease and sepsis. However to unravel the role of 
endotoxins more reliable diagnostic tools than the chromogenic 
endotoxin assay are needed. In the future sensitive radioimmuno assays 
or monoclonal antibodies to lipid A might help us to determine the role 
of endotoxins in liver disease. 
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7.1 SUMMARY 
Increased endotoxin absorption from the intestine, due to changes in 
mucosal permeability, might contribute to endotoxemia in patients wlth 
liver disease. We studied the rate of absorption of 51 chromium-labelled 
Escherichia coli endotoxin from loops of intestine of male Wistar rats. 
Portal hypertension was created by incomplete ligation of the portal 
vein in one group of rats. Ethanol was administered to two groups, 
either in the drinking water (15% w/v) or in a liquid diet to provide 
36% of the energy for a period of three weeks. Ulcerative colitis was 
created in another group by brief exposure of the colon to dilute 
acetic acid. Endotoxin absorption was also studied in vitro in everted 
intestinal sacs. Endotoxin absorption was very low (mean 0. 60, range 
0-2.83 ug/10 em intestine/2 hrs) from both small and large intestine of 
control animals. Neither ethanol administration nor portal hypertension 
increased endotoxin absorption, whereas the absorption rates from the 
colon were raised in rats with colitis (mean 5.83, range 0.10-17.30 
mcg/10 em colon per 2 hrs). Endotoxin absorption was found to be much 
higher from everted sacs than from the intestinal loops in vivo. 
We conclude that the intact intestinal mucosa forms an efficient 
barrier to intraluminal endotoxin. The permeability of the intestine to 
endotoxins is not increased by portal hypertension or by the 
administration of ethanol in rats. Everted intestinal sacs are not 
suitable models for studying the process of endotoxin absorption. 
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7.2 INTRODUCTION 
Endo~oxins are lipopolysaccharide componen~s of the cell wall of 
Gram-negative bacteria. Systemic endot.oxem.ia has been implicated in 
several complications of liver disease, and endotoxins have been shown 
to potentiate the effects of hepatotoxins (1). Systemic endotoxemia, as 
demonstrated by the limulus lysate test (1,2) or radioimmunoassay (3) 
is thought to be due to failure of the reticuloendothelial system of 
the liver to clear the portal blood of endotoxins derived from 
intestinal bacteria (4). The mechanism of intestinal absorption of 
endotoxins is not clear. Using everted gut sacs, Nolan and co-workers 
have found a saturable transport mechanism for endotoxin absorption 
from the rat small intes~ine (5). Endotoxins are macromolecules~ and it 
is possible that permeability changes induced by disease or damage of 
the intestinal mucosa might affect endotoxin absorption. Increased 
endotoxin absorption has indeed been demonstrated in hemorrhagic shock 
(6~7~8), a situation in which damage to the mucosa is likely (9). 
We decided to examine various factors which could possibly affect 
endotoxin absorption in patients with liver disease. We therefore 
studied the effec~s of alcohol administration at t.wo dosage levels, 
portal hypertension following partial ligation of the portal vein and 
experimental colitis on the absorption of 51chromium-radiolabelled 
endotoxin from the rat intestine. To obviate the possible damaging 
effects of inversion of the intestine~ we studied the absorption from 
isolated loops in vivo rather than everted gut sacs in vitro. In a 
single experiment the rate of absorption from everted sacs was compared 
with that from isolated loops in vivo. 
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7. 3 MATERIALS AND METHODS 
Male Wistar rats weighing between 200 and 250 grams, obtained from 
T.N.O., Zeist, were used for the experiments. Portal hypertension was 
created by placing 2 incomplete ligatures around the portal vein as 
described previously (9). Briefly the portal vein is dissected free 
during light ether anaesthesia, a catheter with an external diameter of 
l mm placed alongside, and two ligatures are tied around both catheter 
and portal vein with 4-0 silk. The catheter is then withdrawn. This 
leads to a presinusoidal portal hypertension with a raised portal 
pressure and splenomegaly (10). Ethanol was administered either in the 
drinking water (150 g ethanol, 5 g glucose/L) or in a liquid diet in 
which ethanol provided 36% of the total energy (11). The rats were kept 
on the diet for 3 weeks prior to the absorption studies. 
Experimental colitis was provoked by the method of MacPherson and 
Pfeiffer (12). Under light ether anaesthesia 1 ml of 10% acetic acid is 
instilled in the colon by a rectal canula. After 60 seconds the acetic 
acid is removed by 3 successive washings with distilled water. Within 
48 hrs all rats developed a persistent bloody diarrhoea. The absorption 
studies were performed 10 days later. Two groups of coli tic rats were 
formed~ one for histological examination and one for the absorption 
studies. Three control groups were used - two (one for jejunum, one for 
colon studies) on normal laboratory chow~ one on a liquid diet without 
ethanol (11). Six to eight animals were used per group. 
Absorption studies: under ether anaesthesia a laparotomy was performed 
and a jejunal loop immediately distal to the duodenum was selected and 
two loose ligatures placed approximately 15 ems apart. A catheter with 
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an external diameter of 1 mm was introduced into the lumen by a small 
incision proximal to the first ligature, passed through the ligature 
into the loop and then both ligatures were tightened and the catheter 
fixed to, the proximal jejunum by means of a third ligature (Fig.l). 
BLOOD VESSELS 
Fig.l A loop of intestine is cannulated as shown here, care being taken 
not to damage the blood vessels supplying the intestinal segment. 
Two ml of 51cr-labelled endotoxin solution was introduced into the loop 
by 'the catheter, followed by 0.25 ml of air, and the catheter sealed. 
The abdominal wall was closed and the animals were allowed to regain 
consciousness. Two hours later the animals were stunned and 
exsanguinated by cardiac puncture. The isolated loop was removed 
intact, as were the lungs, kidneys, spleen and liver. A standard small 
weight "Was attached to one end of the intestinal loop and its length 
measured. The organs, blood and the loop were placed in separate test 
tubes and the radioactivity counted in a gamma counter (Automatic Gamma 
1 1 1 
System model 1185, Nuclear Chicago). The radioactivity in blood and 
organs was expressed as a percentage of the total activity in these 
organs plus the activity of the isolated loop. During preliminary 
experiments, the rest of the carcass was also counted, but this 
consistently failed to show any increase in counts over the background 
activity. Absorption was calculated as meg endotoxin/10 em bowel 
length/2 hrs. In the absorption studies on the colon, the colon was 
gently flushed with 0.154 M NaCl until clean, and the last 8 ems of the 
colon used for the isolated loop experiments. 
Everted sacs were prepared from another group of rats as described by 
Nolan et al (5). Two segments of small intestine approximately 15 em 
long were removed from the anaesthetized rat and placed in a solution 
of 0.154 M NaCl and 0.0045 M KCl at 4°C. The intestine was everted over 
a glass rod, one end tied off and 0.75 ml of intestinal solution (0.147 
M NaCl, 0.1 mM CaCl 2, 0.04 M glucose, 0.004 M tris-HCl, pH 7.2, 320 
mOsmol/kg) introduced by a small syringe. The second ligature was then 
placed 10 em from the first. The filled, everted sac was placed in an 
Erlenmeyer flask containing 4.5 ml intestinal solution which contained 
51
cr-labelled endotoxin in a concentration of 2 mg/ml and shaken gently 
in a water bath at 37°C for 2 hrs. Oxygen was passed into· each flask by 
means of a catheter. The whole procedure from abdominal incision to 
start of incubation lasted less than 15 mins. Following incubation the 
solution was removed from within the sac by means of a gauge needle and 
the radioactivity in both internal and bathing fluids measured in a 
gamma counter. Absorption is expressed as meg endotoxin absorbed/10 em 
bowel length/2 hrs. 
Endotoxin (E. Coli 0127:B8, Difco) was labelled with 51cr as described 
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by Braude (13) with some modifications (14). The labelled product was 
checked by chromatography and solubility experiments to exclude the 
presence of free 51 chromate and by passage through a 0.22 um bacterial 
filter to exclude aggregate formation (14). 
Statistical analysis: Differences in absorption between the various 
groups were compared by the Mann-Whitney U test. 
7.4 RESULTS 
Endotoxin absorption in control animals was low from both small and 
large intestine (less than 2.83 mcg/10 cm/2 hrs, table 1). The portal 
hypertensive rats had larger spleens (607 :: 79 mg, mean :!: SD) than 
control animals (405 :: 50 mg, p 0.01) and histological examination 
revealed splenic congestion but no thrombosis of the portal veins. 
Portal hypertension was not associated with an increased absorption of 
endotoxin (table 1). Neither of the two groups which received alcohol 
had an increased rate of endotoxin absorption from the small intestine 
(table 1). 
On microscopical examination, the colons of the rats which had been 
pretreated with acetic acid showed also ulcers which sometimes 
penetrated to the muscularis mucosae. The remaining mucosa was 
oedematous and contained a dense inflammatory infiltrate of lymhpocytes 
plasma cells and granulocytes which extended to the serosa in some 
areas. A purulent exsudate was seen within the lumen. Inflammatory 
infiltrates were also found in the portal areas of the liver in these 
animals, and Councilman bodies were observed. Colitis was associated 
with significantly greater absorption of endotoxin from the colon than 
]J3 
occurred in control animals (~able 1). 
Table L TOTAL ABSORPTION OF ENDOTOXIN FROM INTESTINE 
Jejunum 
controls 
pH 
alcohol 1 
alcohol 2 
liquid diet controls 
everted sacs 
Colon 
controls 
ulcerative colitis 
*p 0.05 vs. controls 
ug/10cm/2hrs. 
mean 
0.60 
0.05 
0.06 
0.05 
0.46 
11.4 
0.33 
5.82 
range 
0.02- 2.83 
0.00- 0.15 
0.00- 0.21 
0.00- 0.13 
0.00- 1.80 
3.5 -26.9* 
o.oo- 1.21 
0.10-17 .30* 
Endotoxin absorption was much higher in vitro in the everted sacs than 
under any of the situations studied in vivo using isolated loops (mean 
11.4 meg, range 3.5-26.9, vs. 0.60, range 0.02-2.83 in vivo, p 0.001). 
Histology of the everted sacs showed some damage to the mucosal cells, 
especially those at the tips of the villi, but without obvious 
ischemic changes. 
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7. 5 DISCUSSION 
The very low rates of absorption of endotoxin from the normal rat 
intestine in vivo, contrasts with the findings in vitro using isolated 
everted gut sacs. The range of absorption we found using everted sacs 
corresponds to the rate of absorption found by Nolan et al (5). The 
histological signs of mucosal damage in everted sacs do not support the 
concept that absorption studies under these circumstances represent the 
situation of the intact mucosa. The damage to the mucosa is probably 
due to manipulation and disruption of the vascular supply, and the 
metabolic status of such preparations is poor (15). A good oxygen 
supp1y is essential for the integrety of the mucosa (4). It therefore 
seems justified to conclude that the everted sac is not a suitable 
model system for the absorption of macromolecules by the intestine. 
The low rates of absorption in vivo suggest that an intact mucosa forms 
a highly effective barrier to endotoxin absorption in the rat. The 
colon and small intestine seem to be equally (im)permeable to 
endotoxins. Gross damage to the colon as seen with acetic acid-induced 
ulcerative colitis does result in an increased rate of endotoxin 
absorption. This finding, and histological changes in the liver of 
these animals, are compatible with the theory that increased endotoxin 
absorption might be one of the main causative factors of the hepatic 
lesions seen in patients with inflammatory bowel disease. 
Acute alcohol administration increases the transferal of horseradish 
peroxidase across the intestinal mucosa (16). We have not studied acute 
alcohol administration, but chronic alcohol consumption at. two dosage 
levels failed to increase the intestinal permeability to endotoxins in 
Jl5 
these experiments. Portal hypertension also failed to induce an 
increased rate of endotoxin absorption. These findings do not exclude 
the possibility of an increased rate of endotoxin in patients with 
liv_er disease, in whom several potentially damaging factors, such as 
protein or phosphate deficiency (17 ,18)' intestinal bacterial 
overgrowth (19 ,20), portal hypertension and relative intestinal 
ischemia, and chronic alcohol consumption may be present 
simultaneously. Possible differences in susceptibility to alcohol 
damage and changes in portal blood flow in various species should also 
be considered. 
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8. l ABSTRACT 
Ascites was collected from six patients with liver cirrhosis and the 
cells isolated. These cells, mainly macrophages, were labelled with 14c 
arachidonic aci~ and stimulated with the calcium ionophore A23187. The 
metabolites formed were separated by HPLC. The main substances formed 
by the ascites cells were leukotriene B 4 , 5-hydroxy-6 ,8, 11,14 
eicosatetraenoic acid and leukotriene c4 • Smaller amounts of 
thromboxane 12-hydroxy-5,8,10 heptodecatrienoic acid and 
6-keto-prostaglandin F lalpha were isolated. Human peritoneal 
macrophages are therefore capable of producing leukotrienes and 
prostaglandins. Production of these s-..ilistances might play a role in 
some of the complications of patients with'liver cirrhosis and ascites. 
122 
8.2 INTRODUCTION 
Eicosanoids (prostaglandins, thromboxanes and leukotrienes) are potent 
mediators w~ich have been reported to be released by bbth rodent and 
human peritoneal and alveolar macrophages (1,2,3,4). The peritoneal 
macrophages used in the reported studies were obtained by washing the 
peritoneal cavity with exogenous fluids. Du and co-workers studied 
human peritoneal macropha.ges from patients undergoing chronic 
ambulatory peritoneal dialysis (3). In such patients concentrated 
glucose solutions are infused into the peritoneal cavity by means of an 
indwelling catheter. This procedure could conceivably influence 
macrophage function. 
We were interested whether peritoneal macrophages present in ascitic 
fluid of patients with portal hypertension were also capable of 
producing leukotrienes and prostaglandins. We isolated peritoneal 
m.acrophages from six patients with ascites due to liver cirrhosis and 
determined the production of arachidonate metabolites by these cells by 
means of high pressure liquid chromatography (HPLC) and 
radioimmunoassay (RIA). 
8.3 MATERIALS AND METHODS 
8.3.1 Patients 
Six patients with ascites were investigated. Four patients had an 
alcoholic liver cirrhosis, one patient a chronic active hepatitis and 
one patient sclerosing cholangitis complicated by a bacterial 
peritonitis caused by enterobacter and E. Coli. One liter of ascites 
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was collected from each patient under sterile conditions 'and 
centrifuged immediately. The cells were isolated by centrifugation, 
stained by May- GrUnwald-Giem.sma method and examined microscopically 
and found to comprise less than 5% granulocytes. 
8.3.2 Materials and chemicals 
Leukotrienes B4 , c4 , n4 and E4 were gifts of Dr. J. Rokach (Merck 
Frosst Canada Inc.), Ca ionophore A23187 was obtained from Hoechst 
(Calbiochem-Behring Inc. USA) prostaglandins n2 , E2 and F2alpha from 
Sigma Chem. Comp.(USA), 6-keto PGFlalpha and 
of Dr. J.B. Smith (Philadelphia, USA). 
thromboxane B2 were 
1-14c arachidonic 
gifts 
acid, 
5-D-(5,6,8,9,ll,l2,14,15-3H(n))-hydroxy-6,8,11,14-eicosatetraenoic acid 
(5-HETE), 3 12-L-(5,6,8,9,11,12,14,15- H(n))-HETE and 15-L-(5,6,8,9,11, 
3 12,14,15- H(n))-HETE were purchased from New England Nuclear. All other 
radiolabelled compounds mentioned below were obtained from the Radio-
chemical Centre of Am.ersham (U.K.): (5,6,8,9,11,12,14,15-3H(n))-leuko-
triene B4, (14,15-
3H(n))-leukotriene c4 , (14,15,
3H(n)) leukotriene 04 , 
6 keto (5,8,9,ll,l2,14,15-3H(n)) prostaglandin Flalpha (5,6,8,9,11,12, 
14,15-3E(n)) thromboxane B2 , (5,6,8,11,12,14,15-
3H(n)) prostaglandin E2 
(5,6,8,11,12,14,15-3H(n)), prostaglandin FZalpha(5,6,8,9,12,14,15-3H(n)) 
prostaglandin n2• Antibodies to TXB2 , PGFZalpha and PGE2 were obtained 
from Institute Pasteur (Paris, France); anti-6-keto-PGFlalpha was 
obtained from Seragen (Boston, USA). 
8.3.3 Chromatographic system 
RP-HPLC of leukotrienes and other lipoxygenase products were carried 
out on a Nucleosil 5 Cl8 column (5). The solvents system (A) was 
tetrahydrofuran/methanol/water/acetic acid (25/30/45/0.1), adjusted to 
pH 5.5 with ammoniumhydroxide. Mobile phases were filtered by vacuum 
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filtering through a millipore filter and degassed with helium (6, 7). 
The flow rate was 0.9 ml/min and the absorption was measured at 280 nm. 
Prior . to use the system was washed with approx 15 ml of water, 
thereafter with approx. 30 ml of a 2 % (w/v) EDTA in water solution, 
and rewashed with water (8). The column was equilibrated with the 
mobile phase (A) at an oventemperature of 37°C. Fractions were 
collected for scintillation counting. After each run (90 min) the 
column was rinsed for at least 60 minutes, because of contamination 
with Ca.ionophore and 14c-AA which run respectively after 115 and 140 
min. RP-HPLC of prostaglandins was performed on a Zorbax C8 column. 
This solvent system (B) contained acetonitrile/benzene/water/acetic 
acid (24/0.2/0.1/76). The flow rate of this eluent was 2.0 m.l/min. 
Fractions were collected for scintillation counting. The column was 
rinsed with acetonitrile for 30 min after each sample to elute the 
lipoxygenase products (5). 
8.3.4 Methods 
Cells were spun down in 500 ml flasks for 10 min. at 800 x g. The 
pellets were combined in a polypropylene 50 ml tube R (Falcon ) and 
centrifuged for 5 min. at 250 x g. The supernatant was decanted, and 
the pellet washed with 20 m1 of distilled water during 10 seconds and 2 
ml NaCl solution (18.9%, w/v) added. The cells were spun down again (5 
min. at 250 x g) and washed until the erythrocytes were removed. 
The pellet, containing white cells, was suspended in 10 ml of 
Krebs-Henseleit buffer. A sample was taken for counting and 
differentiation of the cells. Cell differentiations, based on 
morphology, resulted in 70-80% macrophages, maximally 15% lymphocytes 
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and less than 5% granulocytes. Attempts to purify the macrophages 
population further resulted in increasing numbers of non-viable cells. 
The tube was placed in a water bath of 37°C on a magnetic stirrer (900 
rpm). Through a thin pipette the sample was continuously gassed with a 
mixture of 95% o2 +~5% co2 • Thereafter, 5 uCi (l-14c) arachidonic acid 
(55 mCi/mmol) was added, glutathione (final cone. 2 mmol/1) and 
Ca-ionophore A23187 (1 umol/1). At the end of the 10 min. incubation, 
3H-LTs and 3H-GPs dd d d h h d (10 . were a e an t e omogenate spun own m~n., 
1400 x g, 4°C). The pellet was washed once, and the combined 
supernatants were then applied to a Seppak Cl8 cartridge and the 
effluent was placed on a Seppak silica cartridge. (The Cl8 cartridge 
was prewashed with 10 ml. of methanol and 10 ml. of distilled water; 
the silica cartridge was prewashed with 10 ml of methanol and 100 ml. 
of water (8). The sample was eluted with 2.5 ml methanol on each 
column; these eluates were combined and evaporated to dryness t.rith a 
gentle stream of nitrogen at 40°C. Thereafter, the dried sample was 
dissolved in 1 ml. of solvent A, filtered and kept in a siliconized 
HPLC micro vial. Volumes of 200 ul were injected on the column and 
chromatographed using a 1082B high performance liquid chromatograph 
(Hewlett Packard). Fractions were collected with a Superrac 
fractioncollector (LKB Sweden) and counted in a 3255 Tricarb liquid 
scintillation counter (Packard, Brussels, Belgium (5). 
8.3.5 Quantitative evaluation 
The settings for double labelled scintillation counting were such that 
3 14 there was no spillover of radioactivity of H into the C channel. Dpm 
calculations were carried out, using quenched standard sets. A plotting 
system was programmed in order to obtain data of total counts covering 
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the peak areas. Amounts calculated in dpm of both channels were plotted 
as separate chromatograms. Radioimmunoassay was used to confirm the 
identity of eicosanoid peaks in high performance liquid chromatograms. 
8.4 RESULTS 
Figure 1 shows a representative chromatogram (patient I) of Lis and 
other lipoxygenase products, after 14c-arachidonic acid labelling of 
the cells. The upper part of the figure represents the mass, measured 
by absorption at 280 nm. Only LTC4-like and LTB4-like compounds are 
present in detectable amounts. The curve in bet:ween gives plotted 
14
c-labelled fractions. Prostaglandins cochromatograph with LTC4 , so 
that a not unimportant part of this peak is due to the presence of 
cyclooxygenase products. HHT was characterized by means of experiments 
with platelets in which predominantly TXB2, HRT and 12-HETE is 
synthesized (9). 
The chromatogram given at the bottom of figure 1 shows the added 
3H-labelled substances. In table 1 the recoveries are listed. Data in 
the figures are not corrected for these recoveries. In figure 2 
chromatograms of prostaglandins, obtained from the same sample as 
mentioned in figure 1 are represented. In this case only t.he labelled 
compounds are shown. The upper part gives the formation of 6-keto-
prostaglandin F 1alpha and thromboxane B2 , the lower part the markers 
added to the mixture. 3 H-labelled compounds are shifted to the left. 
The longer the retention time, the greater the delay between the 
different labelled compounds of the same substance. Probably labelling 
of 4 double bounds with 3H makes these substances more hydrofilic than 
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Fig.l. Chromatograms of lipoxygenase products, synthesized by human 
ascites cells (patient Ia), after 14c arachidonic acid loading, 
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in the presence of glutathion (2mmol/l) and Ca-ionophore A23187 
(1 umol/1). Top: absorption (arrows indicate retention times of 
synthetic LTs); middle: 14c-labeled metabolites; bottom: 
3H-labeled standards. 
Table 1. RECOVERIES OF TRITIATED LTs, HETEs and PGs, MEASURED BY HPLC 
Data were obtained after the extraction procedure as described 
in the methods section. Values are given as the mean ~ S.E.M. 
Recovery (%) n 
LTC4 59 " 
5.0 3 
LTD4-like 86 " 
1.5 3 
LTB4 70 " 
5.7 3 
15-HETE 34 
" 
1.1 3 
12-HETE 34 
" 
0.9 3 
5-HETE 18 
" 
0.6 3 
6-keto-PGFlalpha 64 ± 2.9 8 
TxB2 86 ± 2.7 8 
PGF2 44 ± 1.8 8 
PGE2 73 " 
2.9 8 
PG02 59 
" 
2.6 8 
-----------------------------------------------------------------------
these labelled with 14c at the first c-atom (5). 
In tables 2 and 3 the amounts of labelled AA metabolites are given as 
percentages of total formed metabolites. Table 2 lists the lipoxygenase 
and table 3 the cyclooxygenase products. By measuring the absorption of 
the LT at 280 nm, the ratio LTC4/LTB4 was determined. The amount of 
radioactivity of LTC4 was calculated with this ratio from that of LTB4 
(5). Amounts are expressed as percentages of total formed metabolites 
synthesized per 108 viable cells. 
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Table 2, LIPOXYGENASE PRODUCTS BY STIMULATED ASCITES CELLS OF SIX PATIENTS WITH LIVER CIRRHOSIS, 
mean ± SD individual patients 
I II III IV v VI 
number of 
cells x 108 0.54 1.45 2.41 0.39 0.50 1.04 
% viability 91 89 93 98 87 46 
LTB4 31.5 ± 8.3* 40.8* 24 43 24.4 29 27.5 
LTC4 6.3 ± 3 .I 4 9 6.4 9 Sol 1.3 
LTD4 1. 7 ± 1.8 0.6 1.4 5,3 1,0 0.6 
5-HETE 30 ± 16.1 22.5 25 31 34 9.6 58 
12-HETE 2.3 ± 2.9 0.3 1.5 8 2.2 1.0 0.9 
15-HETE 5.5 ± 4.3 8.4 3.2 1.1 12,5 5.3 2.2 
* results expressed as % of total formed metabolites, 
Table 3, CYCLOOXYGENASE PRODUCTS BY STIMULATED ASCITES CELLS OF SIX PATIENTS WITH LIVER CIRRHOSIS, 
number of 
cells x 108 
% viability 
TXB2 
6-keto-PGFlalpha 
HHT 
PGF2 
PGE2 
PGD2 
mean ± SD 
6.0 ' 4.6* 
4.1 ± 2.8 
9 ' 7.8 
1.7 ' 0.9 
0,8 ' 0.3 
1,0 ' 0.5 
I II 
0.54 I. 45 
91 89 
8* II 
3.5 3.7 
9.6 18 
1.3 1.4 
0,5 0.9 
0.4 1.1 
individual patients 
III IV 
2. '•1 0.39 
93 98 
2,5 2 ,I 
1.9 4,1 
2.8 2.9 
0.6 1.6 
0,3 
0.5 0.9 
v 
0.50 
87 
II 
9.5 
19 
3.4 
1.1 
1.4 
VI 
1.04 
46 
1.1 
2 
1.9 
1.9 
I 
1.5 
---------------------------------------------------------------------------------------------------------
w * results expressed as % of total formed metabolites, 
] 
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Fig.2. RPLC separation of prostaglandins in the same sample as in Fig.l. 
6KF = 6-keto PGFlalpha' Tx = TxB2 , F = PGFZalpha' E = PGE2 , 
D = PGD2• 
8.5 DISCUSSION 
In this study of leukotriene and prostaglandin production by ascites 
cells, incubated with arachidonic acid and calcium ionophore, 77.5% of 
the arachidonic acid was converted to lipoxygenase products and 22.5% 
to cyclooxygenase products. The main constituents of the lipoxygenase 
pathway were LTB 4 , 5-HETE and to a lesser degree LTC 4 and LTD 4 . The 
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main cyclooxygenase products were TXB2 , HHT and 6-keto-PGF 1 1 h . Ruman ~a p a 
alve-olar m.acrophages have been reported to produce mainly LTB4 (4). 
Peritoneal macrophages derived from dialysate bags mainly produce LTB4 
and LTC4 (3). Hovtever the ascitic fluid in these latter patients is 
artificial and contains high glucose concentrations. The ascites cells 
used in our study were derived from a less artificial environment. The 
in vivo effects of LTB4 are increased vascular permeability, enhanced 
granulocyte sticking and emigration, resulting in peripheral 
neutropenia and leukocyte accumulation (10). In humans LTB4 has been 
found in the synovial fluid of patients with rheumatoid arthritis (11), 
gouty effusions (12), psoriatic skin (13), inflammed bovtel mucosa (14) 
and in sputum from patients with cystic fibrosis (15). 5-HETE has a 
weak LTB4-like activity in vivo (10). LTC4 and LTD4 can contract smooth 
muscles, causing bronchoconstriction, constriction of the large 
arteries and the coronary arteries, and also cause dilatation of the 
microcirculatory vessels and extravasation of macromolecules from human 
capillaries (16). In patients land 2 a LeVeen peritoneal jugular shunt 
(17) vtas inserted subsequently to treat the ascites. In both patients 
the shunts occluded. One possible explanation is that LTB4 production 
by ascites cells causes cell aggregation and clotting. 
The role of prostaglandins and thromboxanes in the pathophysiology of 
liver failure has been subject of increasing interest during the recent 
years. There is circumstancial evidence that prostaglandin E2 (PGE2) 
helps maintain the .renal blood flow and function in cirrhosis by 
counteracting the effects of vasoconstrictive substances (18). Plasma 
and urinary thrombo:xane B2 (TXB2) levels have been reported to be 
raised in alcoholic liver disease and in the hepatorenal syndrome 
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(19,20). TXB2 is a stable metabolite of thromboxane A2 (TXA2)~ a potent 
vasoconstrictor and potent aggregant and it is therefore possible that 
TXA2 is involved in the pathogenesis of some of the complications of 
cirrhosis such as the hepatorenal syndrome. 
Our finding that peritoneal macrophages in liver cirrhosis are capable 
of producing leukotrienes suggests that the role played by the 
lipoxygenase products of arachidonate may be a fruitful! field for 
further study in liver disease. 
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9 .1 ABSTRACT 
Human and rat peritoneal macrophages and rat Kupffer cells were 
labelled with 14c arachidonic acid and stimulated with the calcium 
ionophore A23187. The metabolites formed were separated by high 
pressure liquid chromatography (HPLC). Human peritoneal macrophages 
formed especially leukotriene 5-hydroxy-6,8,11,14 
eicosatetraenoic acid and small amounts of leukot-riene c4 and 
thromboxane B2 , 12-hydroxy-5,8,10 heptadecatrienoic acid and 6 
keto-prostaglandin Flalpha' whereas rat peritoneal m.acrophages 
mainly produced cyclooxygenase products and in particular 
thromboxane B2 and 12-hydroxy-5,8,10 heptadecatrienoic acid. Rat 
Kupffer cells synthesized mainly cyclooxygenase products such as 
prostaglandin F Zalpha, prostaglandin n 2 and prostaglandin E2 • These 
results indicate that the profile of eicosanoids production by 
macrophages is dependent both on the species and on the tissue from 
which the macrophage is derived. 
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9.2 INTRODUCTION 
It has been reported that macrophages of different origin can 
synthesize both prostaglandins (PGS) and leukotrienes (LTS), when 
activated by several substances (1,2,3). We recently investigated 
the formation of these substances in cells obtained from the ascitic 
fluid of patients with liver cirrhosis. The isolated cells, mainly 
macrophages, were labelled with 14c arachidonic acid (AA) and 
st.im.ulated with Ca ionophore A23187. In these experiments, AA was 
mainly converted to lipoxygenase products (77%), of which 
leukotriene B4 
(5-HETE) were 
cyclooxygenase 
(LTB4) and 5-hydroxy-6,8,11,14 eicosatetraenoic acid 
present in the highest amounts. The most important 
products were 6-keto-PGFlalpha and thromboxane B2 
(TXB2) (3). 
We were interested if there were species and tissue differences in 
the production of eicosanoids. For this reason we compared the 
eicosanoids produced by human ascites cells, rat peritoneal 
macrophages and rat Kupffer cells. 
9.3 PATIENTS AND METHODS 
9.3.1 Patients. Nine patients with ascites were investigated. Seven 
patients had an alcoholic liver cirrhosis, one patient a chronic 
active hepatitis and one patient a sclerosing cholangitis 
complicated by a bacterial peritonitis caused by Enterobacter and E. 
Coli. From each patient two liters of ascites were collected under 
sterile conditions in pyrogen free disposable plastic bags and 
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centrifuged immediately. After resuspending the cells, erythrocytes 
were lysed 2 or 3 times; thereafter the cells were washed once with 
Krebs buffer and finally taken in 10 ml of Krebs buffer. A sample 
was taken for cell differentiation and stained by May-Griinwald-Giemsa 
method and examined microscopically as described earlier (3) and 
found to consist of 70-80% macrophages, maximally 15% lymphocytes 
and less than 5-15% granulocytes. 
9.3.2 Rat Kupffer cells and peritoneal macrophages. Kupffer cells 
(liver macrophages) and peritoneal macrophages were obtained from 
3-month-old female BN/BiRij rats weighing 135-150 g. Sinusoidal 
liver cells were isolated by perfusion and incubation of rat liver 
tissue with pronase and collagenase, as described earlier. The crude 
sinusoidal liver cell suspension was freed from erythrocytes and 
cell debris by density centrifugation in a single layer Nycodenz 
gradient (4). Purified Kupffer cells were obtained by centrifugal 
elutration of the sinusoidal liver cells (5). The Kupffer cells were 
suspended in 10-15 m.l Dulbecco 's modification of Eagles (DME) medium 
containing 20% (v/v) new born calf serum, penicillin (100 units/m.l) 
and streptomycin (100 ug/ml). The cells were then incubated at 3r C 
under 95% o2-5% co2 in a sterile 50 ml Falcon tube for 24hours,. to 
allow the cells to recover from the isolation procedure. The cells 
were harvested by centrifugation, washed and resuspended in ice-cold 
DME medium, before use. 
Peritoneal macrophages were obtained from animals that had been 
injected with either sterile thioglycollate (Merck) 4 days 
previously or 10 ml sterile physiological saline 1 day previously. 
The cells were harvested by a single peritoneal lavage with 50 ml 
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physiological saline. 
9.3.3 Materials. Leukotrienes B4 , c4 , n4 and E4 were gifts of Dr. J. 
Rokach (Merck Frosst Canada Inc.), Ca ionophore A23187 was obtained 
from Hoechst (Calbiochem-Behring Inc. USA), prostaglandins D2 , E2 
and F 2alhpa, 6-keto PGF lalpha and thromboxane B2 from Sigma Chem. 
Comp. (USA), (l-14c)arachidonic acid, 5-D-(5,6,8,9,11,12,14,15-3H(n)) 
-hydroxy-6,8,11,14-eicosatetraenoic acid (5-HETE), 12-L-(5,6,8,9,11,12, 
14,1S-3H(n))-RETE and 3 15-L-(5,6,8,9,11,12,14,15- H(n))-HETE were 
purchased from New England Nuclear. All other radiolabelled compounds 
mentioned below were obtained from the Radiochemical Centre of Amersham 
(U.K.): (5,6,8,9,11,12,14,15-3H(n))-leukotriene B4 , (14,1S-
3H(n))-
leukotriene c 4 , (l4,15-
3H(n))-leukotriene D4 , 6-keto-(5,8,9,ll,l2,14,15 
-
3H(n)) prostaglandin Flalpha' (5,6,8,9,11,12,14,15-3R(n)) thromboxane 
3 B2 , (5,6,8,11,12,14,15- H(n)) prostaglandin E2 , (5,6,8,11,12,14,15 
-
3H(n)), prostaglandin FZalpha'(5,6,8,9,12,14,15-3H(n)) prostaglandinD2 • 
Antibodies to TXB2 , PGFZalpha and PGE2 were obtained from Institut 
Pasteur (Paris, France); anti-6-keto-PGFlalpha was obtained from Seragen 
(Boston, USA). 
Sep-Pak c18 and silica cartridges and HPLC filters RA (0.45 um), FH 
(0.5 um) and Millex (0.45 uM) were obtained from Waters/Millipore 
(The Netherlands). 
Prepacked HPLC columns Nucleosil 5c18 and Zorbax c8 were obtained 
from Chrompack (Middelburg, The Netherlands). 
9.3.4 Chromatographic system. Reversed phase-HPLC (RP-HPLC) of 
leukotrienes and other lipoxygenase products was carried out on a 
Nucleosil 5 column (7). The solvent system (A) was: 
tetrahydrofuran/methanol/0~1% (w/v) EDTA solution in water/acetic 
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acid (25/30/45/0.1) ~ adjusted to pH 5.5 with ammoniumhydroxide 
(7 ~8). Mobile phases were filtered by vacuum filtering through a 
millipore filter and degassed with helium. The flow rate was 0. 9 
ml/min and the absorption was measured at 280 nm. The column was 
equilibrated with the mobile phase (A) at an oven temperature of 
37°C. Fractions were collected for scintillation counting. After 
each run (80 min) the column was rinsed with methanol for at least 
30 minutes~ because of contamination with Ca. ionophore and 14c-AA 
which elute after 115 and 140 min respectively in system A. RP-HPLC 
of prostaglandins was performed on a Zorbax c8 column. The solvent 
system (B) contained acetonitrile/benzene/water/acetic acid 
(24/0.2/76/0.1). The flow rate of this eluent was 2 ml/min. 
Fractions were collected for scintillation counting. The column was 
rinsed with acetonitrile for 30 min after each sample to elute the 
lipoxygenase products (7). 
9.4 METHODS 
The pellets of human peritoneal macrophages, rat peritoneal 
macrophages and rat Kupffer cells were suspended in 10 ml 
Krebs-Henseleit buffer. The tubes were placed in a water bath of 
37°C. The samples were continuously gassed through a thin pipette 
·with a mixture of 95% 02 and 5% co2 • Firstly, 2.5 uCi (1-
14c) 
arachidonic acid (55 mCi/mol), thereafter~ gluthathione (final 
concentration (2 mm.ol/1)) and calcium ionophore A23187 (10 umol/1) 
were added. At the end of the 10 min incubation, serine (5 mmol/1), 
cysteine (10 mmol/1), 3H-LTs and 3H-PGs were added and the 
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homogenates spun down (10 min, 1400 x g~ 4°C). Serine and cysteine 
were added to prevent breakdown of respectively LTC4 to D4 and D4 to 
E4 • T~e pellets were washed once~ and the combined supernatants of 
each cell type were then applied to a couple of Seppak c18 and silica 
cartridges. (The cartridges were prewashed with 10 ml of ethanol and 
10 ml of distilled water (8)). The samples were eluted with 5 ml 
ethanol on each colUlllD.; these eluates were combined and evaporated 
to dryness with a gentle stream of nitrogen at 37°C. Thereafter~ the 
dried samples were dissolved in 0.5 m.l of solvent A, centrifuged and 
purified by a Millex-filter and kept in a HPLC micro vial 
(Weichmann, Switzerland). Volumes of 100 ul were injected on the 
column and chromatographed using a 1082B HPL chromatograph (Hewlett 
Packard). Fractions were collected with a Superrac fraction 
collector (LKB Sweden) and counted in a 3255 Tricarb liquid 
scintillation counter (Packard, Brussels, Belgium). 
Quantitative evaluation. The settings for double labelled 
scintillation counting were such that there was no spillover of 
radioactivity of 3H into the 14c channel. Dpm calculations were 
carried out, using quenched standard sets. A plotting system was 
programmed in order to obtain data of total counts covering the peak 
areas. Amounts calculated in dpm of both channels were plotted as 
separate chromatograms. 
9.5 RESULTS 
Figure I 
produced 
shows a representative chromatogram 
from 14c-labelled arachidonic acid. 
of prostaglandins 
The upper one 
145 
represents the rat ascites cells (70% macrophages) and the lower 
part the rat Kupffer cells. 3H labelled prostaglandins were used as 
references. 
-
llOO 
!4 Fig.!: RP-HPLC chromatograms of prostaglandins produced from C 
arachidonic acid by rat Kupffer cells (upper) and ascites cells 
(70% macrophages) (at the bottom). 
Identification of the peaks: 1: front, 2: 6 keto PGF 
- - !alpha~ 
3: TXB2 , 4: PGFZalpha' 5: PGE2 , 6: PGD2 . 
Figure II shows a RP-HPLC chromatogram of leukotrienes produced from 
14
c-labelled arachidonic acid by hwnan ascites cells (70% 
macrophages). The upper curve shows the absorption of leukotrienes 
at 280 nm. Synthetic LTC4 , LTD4 ~ LTE4 and LTB4 were used as 
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references. The chromatogram at the bottom shows the radioactivity 
of all compounds. 3a labelled leukot.rienes and HETES were used as 
references. 
"" 
-'; l~OO 
i , ... 
! 
' ' 
Fig.II.: RP-HPLC chromatograms of leukotrienes produced from 14c 
arachidonic acid by ascites cells (70% macrophages). The 
upper one shows the absorption of the leukotrienes at 280 
nm. The chromatogram at the bottom shows the radioactivity 
of all the 14c-labelled compounds. 
Identification of the peaks: a: front~ b: -oxidation 
products of LTB4 , c: LTC4 , d: epi, 6 t-LTB4 and 6 t-LTB4 , 
e: LTB4 , f: 12 epi, 6 t, 8 c-LTB4, g/h: di-HETE's. 
1: front, 2: PGs and LTC4 , 3: LTD4 , 4: LTB4 and LTB4-like 
substances (seed and f), 5/6: di-HETE's, 7: 15-HETE, 
8: 12-HETE, 9: 5-HETE. 
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In figure III and IV the percentage (mean :!: SD) of the total formed 
metabolites of respectively the cyclooxygenase and lipoxygenase 
products of the human~ rat peritoneal m.acrophages and rat Kupffer 
Cells are shown as block diagrams. The rat peritoneal macrophages 
stimulated with either saline or thioglycollate did not show 
significant differences of eicosanoids production. The rat Kupffer 
cells produced small amounts of LTC4• 
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CYCLO OXYGENASE PRODUCTS 
0 Rat Kupffer cells 
[] Rat per. M<j> saline 
~ Rat per. M,> thiogl. 
• Human per. Mp 
Fig. III: Graph of total formed cyclooA~genase products expressed as 
percentages (mean :!: SEM) of rat Kupffer cells~ rat 
peritoneal macrophages after stimulation with saline or 
thioglycollate and human peritoneal macrophages. 
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di-HETE 
LIPOXYGENASE PRODUCTS 
0 Rat Kupffer Cells 
E) Rat per. Mf saline 
ll!1iJ Rat per. Mj> th;ogl. 
• Human per. M+ 
LTC/0/E 15-HETE 12-HETE 5-HETE 
Fig. IV: Graph of total formed lipoxygenase products as percentages 
(mean = SEM) of rat Kupffer cells, rat peritoneal 
macrophages after stimulation with saline or thioglycollate 
and human peritoneal macrophages. 
9.6 DISCUSSION 
The results presented here indicate t.ha't the capacity of the three 
different types of macrophages used in this study to produce 
eicosanoids is dependent both on the species and on the tissue from 
which the cells were derived. The human peritoneal m.acrophages, rat 
149 
peritoneal macrophages after saline and thioglycollate and rat 
Kupffer cells converted arachidonic acid respectively for 29%, 61%~ 
74% and 73% to cyclooxygenase products and for 71%, 37%, 25:' and 27% 
to lipoxygenase products. 
Besides the differences of these three cell-types in the total 
lipoxygenase and cyclooxygenase products, the individual eicosanoids 
also show great differences. Ruman peritoneal macrophages mainly 
synthesize LTB4 , 5-HETE and to a lesser degree LTC4 and LTD 4 • The 
main cyclooxygenase products are TXB2 and 6-keto PGF lalpha and only 
trace amounts of prostaglandin E2 (PGE2), prostaglandin FZalpha 
(PGFZalpha) and prostaglandin n 2 (PGD2) were formed. 
Human peritoneal macrophages derived from dialysate bags of patients 
undergoing continuous ambulatory peritoneal dialysis, synthesize 
almost the same pattern of eicosanoids as those described in "this 
study (1,2). 
In contrast to the human peritoneal macrophages, rat peritoneal 
macrophages converted arachidonic acid almost exclusively to TXB2 
and in minor degree to 6-keto PGFlalpha and PGF2alpha; only small 
amounts of leukotrienes being formed. The high TXB2 production of 
these cells is in agreement with earlier work (9). 
The individual .eicosanoids produced by Kupffer cells are totally 
different from those by rat peritoneal macrophages. Kupffer cells 
mainly synthesize PGFZalpha' PGD 2, PGE2 and only trace amounts of 
TXB2 and 6-keto PGFlalpP~ and leukotrienes. 
Macrophages play a central role in inflammation, being both 
producers and targets of inflammatory mediators. It is therefore not 
surprising that much work has been performed on macrophage function 
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in experimental animals. 
The capacity of the three different types of macrophages used in our 
study to produce eicosanoids is dependent on species and on the site 
from with ~he macrophage is derived. Another study reported different 
responses of rabbit hepatic versus alveolar macrophages to endotoxins 
(10). Studies in experimental animals therefore cannot always be 
extrapolated to sick humans. The species and tissue difference of 
eicosanoids production might influence the reaction to different 
stimulations of these cells. 
Rats are much less sensitive to endotoxins than guinea pigs or humans. 
This has been attributed to the number of Kupffer cells in the liver, 
as there is a correlation between increasing number of Kupffer cells 
and increasing sensitivity to endotoxins (11). However species 
differences in the pattern of eicosanoids synthesized may also play a 
role in differing reactions to endotoxins. 
It is possible that varying profiles of eicosanoids may be produced by 
human peritoneal m.acrophages in different diseases. For example a 
cyclic variation in number and activity of the peritoneal m.acrophages 
has been found in fluid obtained from the peritoneal cavity of healthy 
women at laparoscopy (12). Although peritoneal macrophages from 
patients undergoing continuous ambulatory peritoneal dialysis produce 
almost the same eicosanoids as the peritoneal m.acrophages derived from 
patients with ascites due to liver disease (3,13), recently differences 
between peritoneal macrophages derived from healthy volunteers and 
patients on CAPD have been described (14). 
Further studies on the influence of tissue of origin and disease 
status on eicosanoid production by macrophages in humans are needed. 
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Cl!APTER 10 
DISCUSSION 
In chapter 1 the aims of the study are formulated. This chapter contains 
a discussion about the results outlined in chapter 4 to 9 in the light 
of these goals. Eicosanoids (prostaglandins and leukotrienes) are potent 
mediators and play a role in several diseases (1,3,56). JLne most 
important precursor of the eicosanoids is arachidonic acid (3,24,29). 
Administration of endotoxins results in raised levels of several 
prostaglandins such as PGF2alpha' and 6-keto-PGFlalpha 
(168,169,243). The main substance is TXB2 , which is a potent platelet 
aggregator and vasoconstrictor (3,56). Several NSAIDs, such as 
indomethacin, salicylate and ibuprofen improve hemodynamit..:s and 
survival in experimental endotoxin shock (240~241~243). As endotoxemia 
occurs in liver disease~ it is conceivable that several of the 
manifestations of decompensated liver disease are due to endotoxins and 
are mediated by eicosanoids (192,193,195~204). 
The first two questions to be answered were whether thromboxane levels 
are raised in liver disease and whether this correlate with the 
severity of liver disease. 
In twelve out of sixteen patients with alcoholic liver cirrhosis we 
found raised plasma TXB2 levels, as measured by RIA, on one or more 
occasions. Raised plasma TXB2 levels were associated with a disturbed 
renal function as measured by the serum urea level, a disturbed liver 
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function as measured by raised alkaline phosphatase and gamma glutamyl 
transpeptidase levels and disturbed clotting mechanism as measured by 
lower antiplasmin and antithrombin III levels, compared to the values 
obtained by the same twelve patients at times when plasma TXB2 levels 
were normal. There were no significant differences in platelet count, 
leucocyte count and fibrinogen levels between the periods of raised and 
normal plasma TXB2 levels. In the four patients with repeatedly normal 
plasma TXB2 levels the mean platelet count, mean renal function and 
liver function tests and mean clotting factors were less abnormal than 
in the patients with raised plasma TXB2 levels. Two patients with 
raised plasma TXB2 levels died. The mean duration of hospitalisation in 
the group with raised plasma TXB2 levels was 33 days compared to 16 
days in the group with normal plasma TXB2 levels. 
To unravel questions 3 and 4, namely whether raised plasma thromboxane 
levels are involved in the hemodynamic changes and to investigate the 
site of TXB2 production and elimination in liver disease, a 
catheterisation study was performed. In four out of five patients with 
liver cirrhosis we found a net TXB2 production by the splanchnic area 
and in all patients there was a net TXB2 removal by the lungs and 
kidneys. However the administration of dazoxiben, a thromboxane 
synthetase blocker, although reducing plasma TXB2 to normal levels did 
not result in changes in systemic and hepatic pressures or hepatic 
blood flow. 
These two studies show that raised plasma TXB2 levels are present in 
patients with liver disease. These findings are further sustained by 
the findings of Zipser who found raised levels of urinary TXB2 in the 
hepatorenal syndrome (115). The lack of circulatory changes following a 
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decrease in plasma TXB2 levels suggest that the raised plasma TXB2 
levels in cirrhotics might be a secondary phenomenon or that the 
effects of chronically raised TXB2 levels might not be easily 
reversible. In pulmonary hypertension it has been postulated that 
secondary changes in the vessels might be the reason that many 
therapeutic trials with various drugs are not succesfull (253,254). 
This might ah:o be the explanation for the failure of dazoxiben to 
lower portal pressure. Prolonged treatment with dazoxiben in early 
portal hypertension needs to be studied to unravel the role of 
thromboxane in portal hypertension. 
Based on these findings it would seem reasonable to suggest a trial 
with NSAIDs to lower the production of TXB2 in liver cirrhosis. However 
the administration of such drugs have been shown to result in renal 
failure and to give rise to bleeding problems in these patients 
(174,175,176,255). NSAIDs block the whole cyclooxygenase pathway, 
including the production of PGE2 and PGFZalpha. In contrast to TXB2 , 
PGE2 seems to play a supportive role in maintaining renal function in 
cirrhotics (174,176,177). The postulated beneficial effect of some 
prostaglandins on renal blood flow in cirrhotics, provides an 
explanation for the deterioration of renal function after NSAID 
administration. 
Although we tentatively conclude that some of the complications of 
cirrhosis may be mediated by thromboxanes, the clinical experience with 
NSAIDs suggests that some of the other cyclooxygenase products have a 
beneficial function in these patients. 
As we postulated that the raised plasma TXB2 levels were mediated by 
endotoxins in cirrhotics we were interested if raised endotoxin levels 
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were correlated with raised TXB2 levels. 
In sL~ patients with gram negative septicemia proved by positive blood 
cultures and in t~:!elve patients with liver cirrhosis we measured 
endotoxin levels by a Limulus lysate endotoxin assay with the aid of a 
chromogenic substrate and plasma TXB2 levels on one or more occasions 
(202,203). 
In eight of the twelve patients with liver cirrhosis and in three of 
the six patients with sepsis we found endotoxin levels above the 95% 
confidence limit for normals of 12 pg/mL However the variability of 
the standard curves of the endotoxin assay and the lack of sensitivity 
of the assay were considerable. 
In agreement with earlier work we found raised plasma TXB2 levels in 
patients with liver cirrhosis and patients with sepsis (166 ~ 170 ~ 178). 
There was however no correlation between endotoxin and TXB2 levels. 
This might be due to the failure of the limulus assay to detect 
endotoxemia even at levels giving symptoms, as was the case in the 
septic patients~ due to a lack of sensitivity of the assay~ or to time 
related factors. More studies need to be done to unravel the role of 
endotoxins with specific assays to detect endotoxemia in patients. 
Monoclonal antibodies to lipid A, which is remarkably identical for a 
broad spectrum of gram-negative bacteria and which is responsible for 
most of the biological effects of endotoxins~ might be helpfull in the 
future. 
We tried to obtain antibodies to lipid A by immunizing rabbits with 
lipid A-coated bacteria as described by others (256,257). The presence 
of anti lipid A antibodies was detected by a passive hemolysis test. 
We could detect high levels of anti lipid A antibodies in the serum of 
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the rabbits, however further testing revealed some cross reactions with 
whole endotoxins which meant that the anti-lipid-A antibodies were not 
suitable for clinical research. Others have encountered similar 
problems in attempting to develop an antibody against lipid A (A. 
Brouwer, J.P. Nolan, personal communication). In the future more 
specific antibodies to lipid A might help unravel the role of 
endotoxins in several diseases. 
Endotoxemia in liver disease could be due to decreased removal from the 
circulation by the RES or to increased absorption from the gut. 
Question six was the possible contribution of portal hypertension and 
ethanol on the permeability of the intestine to endotoxins. Neither 
portal hypertension nor ethanol in low and high concentrations 
increased the permeability of the intestine to endotoxins in rats. 
These findings do not exclude the possibility of increased endotoxin 
absorption in patients with liver cirrhosis in whom several potentially 
damaging factors, such as portal hypertension and relative intestinal 
ischemia, protein or phosphate deficiency and chronic alcohol 
consumption may be present simultaneously. 
Another possibility we considered was that alcoholism could lead to 
bacterial overgrowth of the small intestine, with concomittant mucosal 
damage and increased endotoxin absorption. We studied seven patients 
with alcoholic cirrhosis with the aid of a breath test, detecting bile 
acid deconjugation by intestinal bacteria (232,233). In five out of 
seven patients we found a late peak after 4 hours. As alcoholics have a 
diminished gastrointestinal motility this peak might be due to 
bacterial overgrowth in these patients. Bode et al found significant 
more anaerobic and aerobic bacteria in the jejunum of patients with 
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alcoholic liver disease .. Bacterial overgrowth of the small intestine, 
which has a much larger absorptive surface than the 
colon and the integrity of which is damaged by bacterial overgrowth, 
migp.t therefore contribute to higher levels of circulating endotoxins 
in these patients (229) .. 
The next question was to investigate the product1on of eicosanoids by 
human per1toneal macrophages derived from patients with liver 
cirrhosis, as little was known about eicosanoid production by 
macrophages in this disease.. The isolated ascites cells (mainly 
macrophages) of six patients with cirrhosis produce mainly lipoxygenase 
products, such as LTB4 , 5-HETE and LTC4 and smaller amounts of the 
cyclooxygenase pathway, namely TXB2 , HHT and 6-keto-PGF lalpha. Thus 
human peritoneal macrophages, when stimulated are capable of producing 
leukotrienes. In view of the similarity between leukotriene effects in 
animals and a number of manifestations of alcoholic liver cirrhosis, 
further studies on the role of LTs in liver disease would be of great 
interest .. Such studies are, however, as yet not possible due to the 
problems inherent in leukotriene detection .. 
Endotoxin administration has diverging effects in different species 
and the effects are also influenced by the route of administration 
(e.g. intravenous v.s .. intraportal) .. 
To investigate the possible species and tissue dependency of the 
ability of m.acrophages to produce eicosanoids, we compared the 
production of eicosanoids by human ascites cells, rat ascites and rat 
Kupffer cells.. In contrast to the human peritoneal macrophages rat 
peritoneal m.acrophages converted arachidonic acid mainly to COP and 
especially TXB2 whereas rat Kupffer cells converted arachidonic acid to 
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COP but especially to PGFZalpha' PGD2, and PGE2 and only trace amounts 
of TXB2• These two studies with macrophages show us that macrophages 
can pr.oduce eicosanoids but that the type of eicosanoid produced is 
dependent both on the tissue and on the species used. 
The possibility that endotoxin effects are in part mediated by 
leukotrienes, and the similarity of many leukotriene effects to changes 
seen in especially alcoholic liver disease opens interesting 
perspectives for further research on the interaction between 
eicosanoids in liver disease. 
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SUMMARY 
Endotoxins are cell ~all lipopolysaccharides of gram negative bacteria. 
In the normal state they are absorbed from the bowel and removed and 
detoxified by the Kupffer cells. Systemic endotoxemia is found in liver 
disease and is at least in part due to a diminished reticuloendothelial 
system (RES) function. Endotoxemia results in disorders of the clotting 
mechanism, renal dysfunction and a high mortality rate. In animals, 
endotoxins induce the liberation of eicosanoids. Eicosanoids is the 
generic name of prostaglandins (PGs) and leukotrienes (LTs). Endotoxin 
administration to experimental animals results in raised levels of 
thromboxane PGFZalpha and 6 keto PGFlalpha· 
Pretreatment of the animals with selective thromhoxane synthetase- or 
prostaglandin blockers improved survival after endotoxin administration. 
The aims of the investigation described in this thesis were to 
determine if raised plasma TXB2 levels were to be found in these 
patients with liver disease and if they could be correlated with the 
complications. 
In addition a study was performed to investigate the 
ability of human macrophages, derived from patients with liver 
disease, to synthesize eicosanoids. In view of the marked 
differences in sensitivity to endotoxins between species and the 
postulated importance of the Kupffer cell for removal of endotoxins 
on the species and site dependence of eicosanoid production by 
macrophages was investigated. 
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In chapter 2 a review of the literature on eicosanoids is given. It 
deals with the precursors, such as linoleic acid, gamma linolenic 
acid and arachidonic acid, of the eicosanoids, the cyclooxygenase 
pathway, which converts arachidonic acid to prostaglandins and 
thromboxanes 
leukotrienes. 
aD.d the lipoxygenase pathway which results 
The importance of eicosanoids in obstetrics 
in 
and 
gynecology, for the lung, the vascular system, the gastro-intestinal 
tract and finally the liver are discussed. 
In chapter 3 a summary is given of the biological effects of 
endotoxins such as fever, hypotension, renal dysfunction and 
clotting disorders. The direct and indirect endotoxin toxicity in 
liver disease and the release of mediators, such as histamine and 
eicosanoids in liver disease are described. 
Plasma TXB2 levels of sixteen patients Yith alcoholic liver disease 
are reported in chapter 4. In twelve patients raised plasma TXB2 levels 
Yere found on one or more occasions. The raised plasma TXB2 levels were 
associated with significantly higher serum levels of urea, alkaline 
phosphatase and gamma glutamyl transpeptidase and laYer antiplasmin and 
antithrombin levels. This study suggests that some of the complications 
in patients with alcoholic liver disease may be mediated by 
thromboxanes. 
In chapter 5 is shown that there is a net TXB2 production by the 
splanchnic area and that TXB2 is removed by the lungs and the kidneys 
in patients Yith liver cirrhosis. Blocking TXB2 production 
by a selective thromboxane synthetase blocker however did not result 
in circulatory changes in these patients. 
In chapter 6 a report is given of the rather disappointing results 
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of our attempts to detect and to quantitite circulating endotoxins 
in cirrhotics and in patients ~ith sepsis. We found that the 
chromogenic limulus assay, although highly specific and sensitive 
for endotoxins in protein-free solutions, failed to detect 
endotoxemia in all patients ~ith bacteraemia. Variability in the 
test itself and the presence of inhibitors in plasma are probably 
responsible. 
In chapter 7 the effect of colitis, portal hypertension and alcohol 
on endotoxin absorption from the rat intestine are described. 
Increased endotoxin absorption from the intestine, due to changes in 
mucosal permeability, might contribute to endotoxemia in liver 
disease. 
The absorption of 51 chromium labelled Escherichia Coli endotoxin 
from loops of intestine of rats were studied. Neither portal 
hypertension nor ethanol administration in concentrations 
increased endotoxin absorption in the rat. Ho~ever the absorption 
rates from the colon were raised in rats with colitis. These 
findings do not exclude the possibility of an increased absorption 
rate of endotoxin in patients with liver disease in whom several 
potentially damaging factors might be present simultaneously. 
In chapter 8 the ability of peritoneal macrophages derived from 
ascites of six patients with liver cirrhosis to produce eicosanoids 
was investigated. The main substances formed by the ascites cells 
were LTB4 , SHETE and LTC4 , whereas smaller amounts of TXB2 , HHT and 
6 keto PGFlalpha were synthesized. 
In chapter 9 an investigation of the species and site differences in 
the ability of macrophages to produce eicosanoids was made. Rat 
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Kupffer cells synthesize mainly PGF Zalpha ~ PGD2 and PGE2 -whereas rat 
peritoneal macrophages mainly produce TXB2 , HHT and 12HETE. 
The human peritoneal macrophages in contrast to the rat Kupffer cells 
and rat peritoneal macrophages, converted arachidonic acid to 
lipoxygenase products such as LTB4 , SHETE and LTC4 and only smaller 
amounts of TXB2 , HHT and 6 keto PGFlalpha -were formed. 
In chapter 10 the results of the studies described in this thesis are 
evaluated in the light of the aims set out in chapter 1. 
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SAMENVATTING 
Endotoxinen zijn celwandbestanddelen van gram negatieve bacterien. 
Na toediening aan proefdieren of aan de mens veroorzaken endotoxinen 
koorts, circulatiestoornissen (o.a. shock, verminderde nierdoor-
bleeding) en veranderingen in leucocyten- en thrombocytenaantal en 
-funktie. Endotoxinen komen voor in de darm. Geabsorbeerde endotoxinen 
worden uit de circulatie genomen door de Kupffer cellen. Bij patienten 
met leverziekten bestaat er een verminderde werking van het reticulo-
endotheliale systeem, waardoor systemische endotoxinemie juist bij deze 
patienten vaak voorkomt. Bij proefdieren induceren endotoxinen vrij-
lating van eicosanoiden. Eicosanoiden is de naam voor prostaglandinen 
(PG) en leukotrienen (LT).. Toediening van endotoxinen aau proefdieren 
gee ft. een verhoogde plasmaspiegel van thromboxaan B2 (TXB£), PGE2 , 
PGFZalpha en 6-keto-PGFlalpha'" Voorbehandeling van dieren met een 
selektieve throm.boxane of prostaglandine synthetase remm.er 
verbetert de overleving na toediening van endotoxinen .. 
Bet doel van de in dit proefschrift beschreven studie was te onder-
zoeken of patienten met leverziekten verhoogde plasma TXB2 spiegels 
hebben en een eventueel verband tussen de verhoogde plasma TXB2 
spiegels en de komplikaties van leverziekten na te gaan.. !evens werd 
onderzocht of menselijke macrophagen, verkregen van patienten met 
leverziekten, in staat waren eicosanoiden te produceren .. 
In het licht van de verschillen in gevoeligheid voor endotoxinen 
tussen verschillende diersoorten en de gepostuleerde rol van de 
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Kupffer eel bij het verwijderen van endotoxinen, werd een studie 
gedaan naar de afhankelijkheid van soort en plaats van macrophagen 
voor produktie van eicosanoiden. 
In hoofdstuk 2 wordt een overzicht gegeven van de literatuur over 
eicosanoiden. De voorlopers van eicosanoiden, zeals linolzuur, gamma 
linoleenzuur en arachidonzuur, cyclooxygenase, die arachidonzuur 
omzet in prostaglandinen en thromboxanen, en lipoxygenase die 
arachidonzuur omzet in leukotrienes, worden besproken. Verder wordt 
ingegaan op de betekenis van eicosanoiden voor de longen, bet vasculaire 
systeem, het maag-darm-stelsel en de lever, alsook in de gynaecologie 
en verloskunde. 
In hoofdstuk 3 wordt een samenvatting van de biologische effekten 
van endotoxinen gegeven. De direkte en indirekte schade die 
endotoxines zou kunnen veroorzaken bij leverziekten, en de afgifte 
van mediatoren - o.a. histamine en eicosanoiden - worden beschreven. 
Hoofdstuk 4 behandelt de resultaten van plasma TXB2 bepalingen bij 16 
patienten met alcoholische levercirrose. Bij 12 patienten werden op 1 
of meer tijdstippen verhoogde plasma TXB2 spiegels gevonden. Deze 
verhoogde plasma TXB2 waarden gingen gepaard met significant hoge 
waarden voor serum ureum, alkalische fosfatase en gamma glutamyl 
transpeptidase en lagere antiplasmine en antithrombine 3 spiegels. Uit 
dit onderzoek wordt geconcludeerd dat enkele komplikaties bij patienten 
~et alcoholische leverziekten .gemedieerd zouden kunnen worden door 
thromboxanen. 
In hoofdstuk 5 wordt aangetoond dat er een netto TXB2 produktie is 
door het splanchnicusgebied, en dat bij patienten met levercirrose 
TXB2 door de long en en door de nieren wordt verwij de rd. Remming van 
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TXB2 produktie door toediening van een selektieve thromboxaan 
synthetase remmer (dazoxiben) bracht. echt.er geen verandering in de 
bloedsomloop bij deze patienten teweeg. 
In hoofdst.uk 6 worden de tegenvallende resultaten bes.chreven van een 
onderzoek naar de mogelijkheid om circulerende endotoxinen bij 
patienten met cirrose en sepsis te kunnen aantonen met een chromogeen 
lymulus lysaat test. Ondanks de hoge specificiteit en sensitiviteit van 
deze test voor endotoxinen in eiwitvrije oplossingen lukte het niet bij 
alle patienten met bacteriemieen endotoxinemie aan te tonen. De 
variabiliteit van de test zelf en de aanwezigheid van plasma inhibitoren 
zijn waarschijnlijk hiervoor verantwoordelijk. 
In hoofdstuk 7 wordt het effekt van colitis, portale hypertensie en 
alcohol op de absorptie van endotoxinen uit de darm van de rat 
beschreven. Verhoogde endotoxinenabsorptie uit de darm tengevolge van 
verandering in de doorlaatbaarheid van de mucosa zou kunnnen leiden 
51 tot endotoxinemie o.a. bij leverziekten. De absorptie van Cr·-gemerkte 
Escherichia coli endotoxinen uit darmlissen van ratten werd bestudeerd. 
Zowel portale hypertensie als alcoholtoediening in 2 concentraties gaf 
geen verhoging van endotoxinenopname bij de rat. Bij de rat ten met 
colitis werd wel een verhoogde absorptie uit bet colon gevonden. Echter 
deze resultaten sluiten de mogelijkheid van een verhoogde absorptie van 
endotoxinen bij patienten met chronische leverziekten niet uit, daar er 
meerdere faktoren gelijktijdig aanwezig kunnen zijn die een toegenomen 
absorptie van endotoxinen veroorzaken. 
In hoofdstuk 8 wordt aangetoond dat macrophagen, verkregen van 
ascites van patienten met levercirrose, eicosanolden kunnen 
produceren. Ascitescellen vormen voornamelijk LTB4 , 5-HETE en LTC4 , 
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en kleinere hoeveelheden TXB2 , BET en 6 keto PGFlalpha· 
In hoofdstuk 9 wordt een onderzoek naar de effekten van diersoort en 
plaats van afkomst van de macrophaag op eicosanoidenproduktie 
beschreven. De rat Kupffercellen maken voornamelijk PGFZalpha, PGD2 
en PGE2 , terwij 1 rat peritoneale macrophagen voornamelijk TXB2 , HHT 
en 12-HETE vormen. Menselijke peritoneale macrophagen zetten 
arachidonzuur voornamelijk om in lipoxygenaseprodukten, zeals LTB4, 
5-HETE en LTC4 , en kleine hoeveelheden TXB2 , HHT en 6-keto-PGFlalpha' 
dit in tegenstelling tot rat Kupffercellen en rat peritoneale macro-
phagen. 
In hoofdstuk 10 worden in het kart de resultaten van de verschillende 
onderzoekingen geevalueerd in het licht van de doelstellingen vermeld 
in hoofdstuk 1. 
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VERANTWOORDING 
Dit proefschrift werd bewerkt op de afdeling Inwendige Geneeskunde II 
in samenwerking met de afdeling Farmacologie van het Academisch 
Ziekenhuis Rotterdam-Dijkzigt. 
Velen ben ik dank verschuldigd bij de totstandkom.ing van dit 
proefschrift~ enkelen wil ik hier met name noemen. 
Met mijn promotor prof. J.R.P. Wilson heb ik gedurende een aantal 
onderzoeken mogen samenwerken. Deze periode heb ik als uiterst leerzaam 
en plezierig ervaren. Zijn enthousiasme, optimisme en 
relativeringsvermogen zijn een belangrijke steun geweest. Zelfs in de 
weekenden was hij bereid mij te helpen met de ontwikkeling van 
monoclonale antistoffen tegen Lipid A. De vrijheid die hij mij tijdens 
het onderzoek heeft gegeven, heb ik zeer ge~aardeerd. 
Mijn tweede promotor prof.dr.I.L. Bonta wil ik bedanken voor de 
waardevolle adviezen en voor de goede samenwerking met. zijn afdeling 
gedurende de afgelopen jaren. 
Dr.J.E. Vincent dank ik voor de krit.ische opmerkingen over mijn 
artikelen en de inhoud van mijn dissertatie. 
Zender de voortreffelijke hulp van Freek Zijlstra bij de bepalingen 
van thromboxanen en leukotrienen in de afgelopen jaren was dit 
proefschrift niet in deze vorm tot stand gekomen, mede dankzij zijn 
kennis over HPLC hebben wij de productie van eicosanoiden bij 
menselijke cellen kunnen aantonen. 
Ook de hulp van Anja van de Broek bij de laboratorium bepalingen dient 
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vermeld te worden. 
De medewerkers van het laboratorium Inwendige Geneeskunde II en met 
name Trinette Rietveld en Wim van de Berg, ben ik zeer erkentelijk voor 
de endotoxinen bepalingen met behulp van chromogeen substraat. 
Marjolein Bakker -en Tom Boks zijn mij in de afgelopen jaren zeer 
behulpzaam geweest bij het verzamelen van de vele bloedmonsters. 
Oak dienen de vele collegae en verpleegkundigen, met name van de 
afdeling 4 midden, genoemd te worden, die de afgelopen jaren ascites 
monsters voor mij hebben verzameld. 
Prof.dr. M. Frenkel, bij wie ik mijn opleiding tot internist heb 
genoten, ga£ mij de gelegenheid tot het verrichten van wetenschappelijk 
onderzoek tijdens mijn opleiding. Ik ben hem hiervoor zeer erkentelijk. 
Alle lof komt toe aan Ellis van der Waarde-Masthof£, die op zeer 
nauwgezette wijze al het typewerk voor deze dissertatie verrichtte. Ik 
heb grote waardering voor haar inzet in dezen. 
Mijn maatschapleden in het Ikazia Ziekenhuis, Cees, Fred en Matthieu, 
dank ik voor de gegeven ruimte om mijn proefschrift te voltooien. 
Mijn vrouw Eugenie wil ik tenslotte bedanken voor het begrip wat zij 
getoond heeft tijdens bet bewerken en schrijven van mijn proefschrift. 
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CURRICULUM VITAE 
De schrijver van dit proefschrift werd geboren op 29 december 1952 
te Delft. Na de MULO-B opleiding werd in 1972 het eindexamen HBS-B 
afgelegd aan de Stedelijke Scholengemeenscf..ap nHugo Grotius11 te 
Delft. 
In dat zelfde jaar werd een aanvang gemaakt met de studie in de 
geneeskunde aan de Rijksuniversiteit te Leiden, alwaar in 1977 het 
doctoraal examen en in januari 1979 het artsexamen werden afgelegd. 
Op 1 april 1979 werd de opleiding tot internist begonnen aan de 
Afdeling Inwendige Geneeskunde II, onder leiding van prof.dr. 
M. Frenkel. 
Op 1 december 1984 werd hij als internist ingeschreven in het 
specialistenregister. 
Sinds februari 1985 is hij in deze funktie werkzaam in het Ikazia 
Ziekenhuis te Rotterdam. 
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